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Summary 
In 2009, approximately 1.7 million people died of tuberculosis.
1
 The emergence of drug-resistant 
strains of Mycobacterium tuberculosis (M. tuberculosis) has created an urgent demand for the 
development of new anti-tuberculosis (anti-TB) drugs and treatments.
2 
M. tuberculosis, the 
causative agent, has a protective complex cell wall structure that is essential for its survival. One 
of the major building blocks of the cell wall structure is an arabinofuranosyl polysaccharide 
called arabinan.  Since arabinan is not present in mammals, it has become a promising target for 
anti-TB drug development.
3 
The arabinan component is biosynthesized by a family of 
arabinofuranosyltransferases (araTs) using the substrate decaprenolphosphoarabinose (DPA) as 
the donor of arabinose. (Figure S.1a).
4,5
 
This project targets the biosynthesis of arabinan by synthesizing analogues of DPA as potential 
inhibitors of araTs. A sulfamide moiety was chosen as an isosteric replacement of the phosphate 
group of DPA.  To mimic the polyprenyl chain of DPA, a series of alkyl chains of varying length 
and a triethylene glycol (TEG) derived chain were used (Figure S.1b).  
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Figure S.1. (a) The structure of DPA. (b) The structure of sulfamide analogues of DPA. 
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Abbreviations 
Ac   acetyl  DPA  decaprenyl phosphoarabinose 
AG  arabinogalactan  EMB ethambutol 
anti-TB anti-tuberculosis   eqv. equivalent   
Aq   apparent quartet   ESI  electrospray ionization 
Araf   arabinofuranose   et al.  et alia (and co-workers) 
araT(s) arabinofuranosyltransferase(s)  ether diethyl ehter 
Bn   benzyl  EtOAc ethyl acetate 
Bu  butyl  Galf  galactofuranose 
Bz  benzoyl   GlcN-c 2-acetyl-2-amino-
glucopyranoside 
c concentration  h hour(s) 
d  doublet  Hz hertz 
DCM   dichloromethane  IR  infrared 
dd  doublet of doublets  J   coupling constant 
DIPEA N,N-Diisopropylethylamine  LAM lipoarabinomannan 
DMAP   4-(dimethylamino)pyridine  m mutiplet  
DMF   N,N-dimethylformamide  mAG mycolyl-arabinogalactan 
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ManLAM mannan capped 
lipoarabinomannan 
 petrol petroleum ether boiling in the range 
of 40 - 60 °C 
Manp  mannopyranose   quin. quintet 
M. bovis 
BCG 
Mycobacterium bovis 
Bacillus Calmette-Guérin  
 R generic group 
mCPBA 3-chloroperbenzoic acid  Rf retention factor 
MDR-TB multidrug-resistant 
tuberculosis 
 r.t. room temperature 
Me methyl  s  strong (in IR spectroscopy)/ singlet 
(in NMR spectroscopy) 
MHz megahertz   t triplet 
MIC minimum inhibitory 
concentration 
 TB Tuberculosis 
 
min minute(s)  TEG triethylene glycol 
m.p. melting point  TMSBr trimethylsilyl bromide 
M. smegmats Mycobacterium smegmatis  TMSOTf trimethyl triflate  
M. 
tuberculosis  
Mycobacterium tuberculosis  tBuH tert-butyl alcohol  
m/z mass/charge ratio   THF tetrahydrofuran 
NMR nuclear magnetic resonance   TTBP 2,4,6-tri-tert-butylpyrimidine 
Pd-black palladium black  XDR-TB extensively drug resistant tuberculosis 
Pd-C palladium on carbon    
Explanatory Note 
vii 
 
Explanatory Note 
The carbohydrate and their derivatives detailed in the thesis are numbered according to the 
carbohydrate convention and named as suggested by the IUPAC recommendations of 1996 (Pure 
Appl. Chem. 1996, 68, 1919). The two protons on C-5 for pentose sugars are labeled H-5 and H-
5‟. 
 
N-octyl-N’-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 67 
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Chapter 1: Introduction 
1.1 Tuberculosis 
Tuberculosis (TB) is contagious and airborne. It is a disease of poverty affecting mostly young 
adults in their most productive years. In 2009, 1.7 million people died from TB, a figure that is 
equivalent to 4700 deaths a day.
1 
A major global issue is the emergence of drug-resistant strains 
of TB, multidrug-resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB).
1,6-8 
MDR-TB is a form of TB that is difficult and expensive to treat, and fails to respond to standard 
front-line drugs.
1 
The current front-line drugs are isoniazid 1, rifampicin 2, pyrazinamide 3, 
ethambutol (EMB) 4 and streptomycin 5 (Figure 1.1).
3
 The standard treatment for TB consists of 
dosage with isoniazid, rifampicin, and pyrazinamide for two months, followed by continuation of 
dosage with isoniazid and rifampicin for six months.
9 
This treatment is generally supplemented 
with EMB or streptomycin, and requires strict adherence to the regime.
3 
Poor management of the 
treatment regime is one of the factors that gives rise to MDR-TB.  For the treatment of MDR-
TB, the regime must be altered, and second-line antibiotics are often employed.
10 
Extensively 
drug-resistant TB (XDR-TB) is said to occur when resistance to second-line drugs develops on 
top of MDR-TB. To date, XDR-TB cases have been confirmed in 58 countries.
1 
New anti-TB 
drugs as well as new drug targets against TB are therefore in urgent need. 
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Figure 1.1. The structures of the first line anti-TB drugs.
3 
 
Polysaccharides composed of furanose residues are important constituents of glycoconjugates of 
many bacteria,
11
 protozoa,
12
 fungi
13
 and plants.
14 
In Mycobacterium species, galactose and 
arabinose are the most common sugars found in the cell wall.  In M. tuberculosis, 
lipoarabinomannan (LAM) and mycolyl-arabinogalactan (mAG) are the two major building 
blocks of the cell wall (Figure 1.2).
3 
LAM is a polymer of mannopyranose (Manp) and 
arabinofuranose (Araf) residues, and is attached to the plasma membrane through a phosphatidyl 
inositol anchor. The mAG complex consists of a polymer of galactofuranose (Galf) and araf 
residues covalently linked to the peptidoglycan at the reducing end, which is esterified at the 
non-reducing end with mycolic acids and branched-chain lipids found in mycobacteria and other 
actinomycetes. Other components of the cell wall complex of mycobacteria include 
peptidoglycan, a polymer of N-acetylglucosamine, N-glycolylmuramic acid and short cross-
Introduction 
3 
 
linked peptides, and glycolipids that are bound through noncovalent interactions with mycolate 
esters.
15,16,17 
Figure 1.2. Schematic representation of the general structure of the mycobacterial cell wall.
3 
 
The thick, multilayered cell wall complex serves as a protective shell against threats from the 
surrounding environment including many classes of antibiotics.
18 
The integrity of the cell wall is 
essential for bacterial survival. In fact the front-line anti-TB drugs EMB 2 and isoniazid 1 
interrupt cell wall biosynthesis and thus allowing other drugs (eg, rifampicin 4 or streptomycin 
5) to enter the organism more easily.  Mycobacterial viability is dependent upon the ability of the 
organism to produce an intact wall.
3 
The biosynthesis of cell wall is therefore an attractive target 
for the development of new drugs for treating tuberculosis.  This project focuses on inhibition of 
Introduction 
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the biosynthesis of arabinan, which is one of the major and essential components of the cell wall 
and which is not present in mammals.
19
 
 
1.2 Arabinan 
In M. tuberculosis the arabinan domain, which is composed of entirely arabinose residues in the 
furanose ring form, found in both LAM and mAG. In mAG the arabinan is predominantly an α-
(1→5) linked linear polysaccharide of araf units with critically positioned α-3,5-branch sites to 
which another linear chain is attached via the 3 position. A β-(1→2) linkage marks the “end 
point” of the arabinan biosynthesis before decoration with mycolic acid.20 The non-reducing 
termini of these arabinan chains are capped with a unique Ara6 motif composed of a branched 
hexasaccharide Arafβ-(1→2)Arafα-(1→5)[Arafβ-(1→2)Arafα-(1→3)]-Arafα-(1→5)Arafα-(1→ 
(Figure 1.3a) of which approximately two-thirds have mycolic acid residues which are esterified 
at all four primary hydroxyl groups, whilst the remaining hexasaccharide motifs are 
unsubstituted (Figure 1.3b).
3,16,21 
The arabinan domain of LAM is a structure similar to that of 
AG in which similar linkages of Araf units are found.
22 
One of the distinctive features is that a 
linear Ara4 motif Arafβ-(1→2)Araf-α(1→5)Arafα-(1→5)Arafα-(1→ coexists with the 
hexasaccharide motif at the non-reducing termini of the arabinan, and these oligosaccharide are 
not esterified with mycolic acids. Instead, the two motifs are either unsubstituted or further 
glycosylated with either a mono Manp, a dimannoside Manpα-(1→2)Manpα or a trimannoside 
Manpα-(1→2)Manpα-(1→2)Manpα to give ManLAM (Figure 1.3c).18,20 The terminal mannose 
residues are believed to be involved in the infection process through the binding to human 
mannose lectins.
3,23,24
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The arabinan domain is synthesized by a family of enzymes called arabinofuranosyltransferases 
(araTs).
3
 
 
Figure 1.3. The structure of non-reducing termini Ara6 motif: a) unsubstituted Ara6 motif; b) Ara6 motif 
esterified with mycolic acids; c) Ara6 motif glycosylated with Manp residues.
18,20 
 
1.3 Arabinofuranosyltransferase 
AraTs have been able to be identified as integral membrane enzymes with the active sites located 
on the periplasmic side of the plasma membrane. They belong to the glycosyltransferase GT-C 
superfamily, carrying the proposed GT-C motif of polyprenyl-dependent glycosyl 
transferases.
25,26 
To date none of the araTs has been successfully isolated. However through 
microbiological studies and cell free-assays several araTs in M. tuberculosis have been able to be 
identified and characterised.
27,28,29
 The identified araTs could be devided into two groups. One 
group known as being the targets of the anti-TB drug EMB 2 includes EmbA, EmbB, EmbC; 
The other group which is insensitive to EMB 2 includes AftA, AftB, AftC and AftD.
30-34
 Each of 
the enzymes is responsible for synthesizing one part of the arabinan domain of AG or LAM in 
M. tuberculosis, although some parts of the arabinan may require the combined activity of two or 
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more enzymes. EmbA and EmbB acted in coordination to synthesize and transfer the 
disaccharide Arafβ-(1→2)Arafα onto the 3-arm of the linear Arafβ-(1→2)Arafα-(1→5)Arafα-
(1→5)Arafα-(1→ to complete the formation of hexasaccharide Ara6 motif at the non-reducing 
termini of AG;
35,36 
EmbC is involved in the elongation of the arabinan domain of LAM;
31 
AftA 
catalyzes the addition of the first key araf residue onto the galactan domain of AG, thus “prime” 
the galactan backbone for the further attachment of α-(1→5) linked araf residues;37 AftB is 
required for forming terminal β-(1→2) linked araf residues, which marks the end point of AG 
arabinan biosynthesis;
38 
AftC is involved in the synthesis of internal α-(1→3) branchings of AG 
arabinan;
39 
AftD, a recently discovered araT, is believed to catalyze the internal α-(1→3)-
branching of arabinan of both AG and LAM.
20 
Figure 1.4a shows the catalytic roles of each araT 
in the biosynthesis of arabinan of AG.
38 
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(a) 
(b) 
Figure 1.4. (a) The roles of each araT in the biosynthesis of arabinan of AG.
38 
(b) The structure of the 
substrate donor DPA.
4 
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Although considerable progress has been made towards understanding the biosynthetic pathway 
of arabinan domain of AG and LAM, there is still much that remains unknown.
25,40,41 
How the 
arabinan and other domains of AG and LAM are assembled. For example if the arabinan grows 
stepwise from the reducing end towards the nonreducing end through the sequential addition of 
glycosyl residues, or if it is assembled through the polymerization of building blocks.
23
 
Nevertheless it is believed that all of the araT use one Araf donor substrate, decaprenyl 
phosphoarabinose (DPA) (Figure 1.4b).
4 
The acceptor substrates for the araTs are the growing 
arabinogalactan polysaccharides. Although the natural acceptor substrates for these enzymes are 
lipid-bound intermediates, these AraTs also recognize small oligosaccharides.
27,42
 
 
The traditional anti-TB drugs like EMB target three or more of the araTs involved in arabinan 
biosynthesis. The synthesis of DPA analogues would provide potential inhibitors that could 
target all araTs, which would be particularly important for treating MDR-TB and XDR- TB. In 
fact, in recent years most of research effort aimed at inhibition of arabinan biosynthesis has 
focused on the development of DPA analogues.
18
 Work done by Lowary et al. has been 
particularly remarkable in this field. In 2002 they synthesized a group of C-phosphonate 
analogues of DPA (Figure 1.5), which were tested against M. tuberculosis strain H37Rv using 
microplate “Alamar Blue” Assay.43 “Alamar Blue” assay is a nonradioactive, rapid, inexpensive, 
and high-throughput method for screening new drug candidates. The Alamar blue oxidation-
reduction dye (alamarBlue
®
) is a general indicator of cellular growth and/or viability. It is added 
to the living culture containing the test compound which is present in increasing concentrations, 
and then incubated for at least 12 hours at 37
o
C. The natural reducing power of the living cells 
normally reduces the dye from its blue, non-fluorescent oxidized form to the reduced form which 
Introduction 
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is fluorescent and pink in color. The nonviable and damaged cells in contrast have none or 
limited ability to reduce the blue dye. Changes in color are measured with a fluorometer or 
spectrophotometer or determined by a visual color change and a value of minimum inhibitory 
concentration (MIC) of the test compound can therefore be obtained.
44
 During the “Alamar 
Blue” assay, compounds 6-9 were inactive towards the growth of the bacteria whilst compound 
10 was found to have a MIC value of 3.13 µg/mL. Based on these results, the C-phosphonate 10 
is currently being tested for efficacy in tuberculosis-infected mice.
43 
 
Figure 1.5. C-phosphonate analogues of DPA synthesized by Lowary et al.
43
 
 
Given this success, T. Lowary et al. synthesized a series of glycosyl sulfone DPA analogues
45
 
and phosphinic acid-containing DPA analogues
46
 (Table 1.6a), which were then tested against M. 
tuberculosis strain H37Rv in the “Alamar Blue” assay. However compounds 11 - 22 showed only 
low to moderate activity towards the growth of bacteria, and none of them was found to be as a 
potent inhibitor as C-phosphonate analogue 10 (Table 1.6b). Lowary concluded at that point that 
there was no clear correlation between structure and the biological activity.
45 
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(a) 
Compound                                                                             % Inhibition                
10 (MIC = 3.13 µg/mL)                                                                         92 
11                                                                                                             0 
12                                                                                                           21  
13                                                                                                           45 
14                                                                                                             0 
15                                                                                                             4 
16                                                                                                             0 
17                                                                                                           20 
18                                                                                                             0 
19                                                                                                             0 
20                                                                                                           17 
21                                                                                                             0 
22                                                                                                             0 
 
(b) 
Table 1.6. (a) The structures of sulfone analogues of DPA (11 – 17)48 and phophinic acid-containing 
analogues of DPA (18 – 22) synthesized by Lowary et al.49 (b) The MIC values of DPA analogues 10 – 
22 against the growth of M. tuberculosis strain H37Rv obtained in the “Alamar Blue” assay.
45
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In contrast to Lowary‟s work, Besra synthesized a series of phosphate DPA analogues with 
polyprenol chain of varying length (24 - 28) (Figure 1.7), which were tested in a cell free assay 
with extracted araTs of Mycobacterium smegmatis (M. smegmatis) and synthetic acceptors. It 
was found that only the long chain polyprenol analogues 24 and 25 were recognized by the 
active site of araTs as arabinose donor substrate. Thus it was concluded that the hydrophobicity 
of the side chain plays an important role in substrate recognition.
28 
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Figure 1.7. Phosphate analogues of DPA synthesized by Bersa G. C. et al. and the activity of each 
compound in the cell free assay of araTs of M. smegmatis.
28 
1.4 Aim of the project 
When designing DPA analogues as potential araT inhibitors, three factors should be considered. 
Firstly, the compound should bind well to the enzyme active site. Secondly, the compound must 
not be able to donate arabinose residues to the acceptor substrate. Thirdly, the compound should 
be stable and non-hydrolysable in a biological environment. With these three attributes, such a 
compound could potentially bind to all araT active sites without being turned over, therefore 
effectively inhibiting arabinan biosynthesis for both AG and LAM.  
 
The aim of this project was to synthesize novel sulfamide analogues of DPA and to test their 
biological activity with “Alamar Blue” assay. Based on the work of Besra28 and Lowary,45,46 the 
effects of increasing the alkyl chain length as well as the insertion of oxygen atoms into the 
linear alkyl chain on the inhibition of mycobacterial growth were also investigated. 
 
0 
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Chapter 2: Results and discussion 
2.1 Synthesis of Glycosyl Sulfone DPA Analogues  
Ayers, a former member of the Fairbanks group, synthesized sulfone DPA analogues (scheme 
2.1) which were tested against the growth of Mycobacterium bovis Bacillus Calmette-Guérin (M. 
bovis BCG) using the “Alamar Blue” assay.47  
 
Scheme 2.1. The synthesis of sulfone DPA analogues by Ayers. Reagents and conditions: (i) AcCl, 
MeOH r.t., 6 h, 80%, α:β, 4:1; (ii) NaH, BnBr, DMF, r.t., 16 h, 87%; (iii) 80%  AcOH (aq), 115oC, 48 h, 
73%; (iv) Ac2O, pyridine, r.t., 16 h, 94%, α:β, 1.7:1; (v) TMSBr, DCM, 40
o
C to r.t., 0.5 h, α:β, 4:1; (vi) 
RSH, TTBP, CH2Cl2, r.t., 16–17 h; 34a, 94%, 34b, 85%, 34c, 83%, 34d, 80%, 34e, 63%, 34f, 97%, 34g, 
80% (all over two steps); (vii) mCPBA, NaHCO3, DCM, 16 h; 35a, 83%, 35b, 78%, 35c, 84%, 35d, 88%, 
Results and Discussion 
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35e, 87%, 35f, 83%, 35g, 86%; (viii) H2, 10% Pd on C, MeOH or MeOH:EtOAc, 1:1, or EtOAc, r.t., 24 
h; 36a, 72%, 36b, 82%, 36c, 80%, 36d, 75%, 36e, 94%, 36f, 88%, 36g, 81%.
47
 
 
The thioglycosides were synthesized from reaction of glycosyl bromide 33 and a series of alkyl 
thiols in the presence of TTBP. This reaction was completely stereoselective and afforded only 
the β-anomers 34a - g in excellent yields (63-94% over two steps). It is believed that the β 
anomeric configuration of the sugar donor is important for the substrate binding to the active site 
of araTs. In the “Alamar Blue” assay, compounds 36a - g exhibited low to moderate inhibitory 
activity towards the the growth of M. bovis BCG (Table 2.1).
47
 However, an increase in the 
inhibitory activity along with the increase in the alkyl chain length was observed from compound 
36a - e, indicating a possible correlation between the alkyl chain length and the inhibitory 
activity of the compound.   
Sulfone DPA analogues MIC (µg/mL) 
36a 2000 
36b 500 
36c 250 
36d 125 > X> 62 
36e 62 
36f 250 
36g 250 > X > 125 
 
Table 2.1. The MIC values of sulfone DPA analogues 36a – 36g against the growth of M. bovis BCG 
obtained in the “Alamar Blue” assay.47 
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2.2 Synthesis of Glycosyl Triazole DPA analogues 
Wilkinson, another Fairbanks former group member, synthesized a series of glycosyl triazole 
analogues of DPA
 
(Scheme 2.2)
48
 and two sulfamide analogues of DPA (unpublished work).  
 
The intermediate glycosyl azide 38 was synthesized by reaction of glycosyl bromide 33 with 
sodium azide. In contrast to the synthesis of 34a - g, the reaction did not proceed with complete 
stereoselectivity. Instead, the reaction afforded compounds 39a - g as anomeric mixtures with the 
desired β-anomer predominating (α:β, 1:2).  
Results and Discussion 
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Scheme 2.2. The synthesis of triazole DPA analogues by Wilkinson. (i) NaN3 (5.0 equiv), Bu4NHSO4 
(1.0 equiv), 1:1 DCM:NaHCO3 (aq), α:β, 1:2, 43% β; (ii) 37a – f (5–10 equiv), CuI (1.0 equiv), DIPEA 
(1.0 equiv), 110
o
C, 72–92%; (iii) NaOCH3 (0.4 equiv), MeOH and THF (2:1 v/v), 92–100%.
48
 
 
In the assay, compounds 40a-f exhibited low to moderate inhibitory activity towards the growth 
of M. bovis BCG (Table 2.2).
48
 Amongst all of the triazole DPA analogues compound 39d has 
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the lowest MIC value which possibly indicates that the active site of araTs favor the hydrophobic 
chain of a certain length. 
Triazole DPA analogues MIC (µg/ml) 
40a 500 
40b 62 
40c 250 
40d 31 
40e 62 
40f No activity 
 
 Table 2.2. The MIC values of sufone DPA analogues 40a – 40f against the growth of M. bovis BCG 
obtained in the “Alamar Blue” assay.48 
 
2.3 Synthesis of Sulfamide DPA Analogues 
2.3.1 Synthetic Strategy 
In the cell wall of M. tuberculosis, all the arabinose residues are in their furanose-ring form. 
Commercially available D-arabinose exists in solution as an equilibrium mixture of acyclic and 
cyclic forms, with the later as the majority. Cyclic D-arabinose consists of both pyranose and 
furanose isomers and at equilibrium, the pyranose form predominates.
49 
To obtain the desired 
arabinofuranose, the first step of the synthetic pathway was to constrain the D-arabinose into the 
furanose configuration. Appropriate protecting groups were then used for the hydroxyls to afford 
a donor suitable for glycosylation with a sulfamide acceptor incorporating a variety of side 
chains. The sulfamide group was chosen as a potential isosteric mimic of the metabolically labile 
phosphate group of DPA.
50 
The sulfamide acceptors were prepared from the commercially 
available chlorosulfonyl isocyanate and a range of commercially available alkyl amines, or a 
Results and Discussion 
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TEG derived amine which was synthesized in the laboratory.
51 
The anomeric configuration of the 
glycosyl sulfamide final product must be β in order to be isostructural with DPA.  This could be 
potentially achieved either by stereoselective sulfamidoglycosylation (Scheme 2.3a), or through 
the direct sulfamidoglycosylation followed by isolation of the β-anomer using flash 
chromatography (Scheme 2.3b).
 
 
(a) 
 
(b) 
Scheme 2.3. (a) Retrosynthetic pathway for direct synthesis of sulfamide. (b) Retrosynthetic pathway for 
stereoselective synthesis of sulfamide. 
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2.3.2 Preparation of the Arabinose Donor 
The starting material D-arabinose 28 is mainly in its pyranose form when dissolved in the 
solution (Scheme 2.4)
52 
 
 
Scheme 2.4. The forms of D-arabinose dissolved in the solution.
52
   
 
A Fischer glycosylation was used to afford the methyl-α,β-D-arabinofuranoside 29. The reaction 
mechanism is shown in scheme 2.5.
53
 The starting material D-arabinose was stirred in methanol 
under acidic conditions (AcCl 1.3 eqv.). The furanoside 29 was the kinetic product and formed 
fast through pathway a. The reaction progress was monitored by t.l.c. using a mobile phase of 
DCM : MeOH, 4:1. The reaction was quenched with pyridine after a three-hour period to avoid 
the formation of the undesired pyranose form (thermodynamic product).
49 
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Scheme 2.5. Compound 29 obtained by Fisher glycosylation.
53 
 
The benzyl ether was chosen as the protecting group for the rest of the hydroxyls of 29. Other 
common protecting groups like tert-butyl dimethyl silyl ether (TBDMS) and benzoyl ether were 
Results and Discussion 
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not suitable in this project: TBDMS would not be stable to the required acid hydrolysis step 
needed for the synthesis of compound 41, whilst the use of benzyl ether protecting group would 
result in the formation of the undesired α-anomer as the predominant product which was due to 
the neighboring group participation. Methyl-α,β-D-arabinofuranoside 29 was submitted to 
standard benzylation conditions to afford methyl 2,3,5-tri-O-benzyl-α,β-D-arabinofuranoside 30 
(70%, α:β, 2.8:1). The anomeric ratio was determined by 1H-NMR (H-1β, 4.89 ppm, d, J1-2 
4.1Hz; H-1α, 4.95 ppm, s). The position of the anomeric proton of compound 75 in 1H-NMR was 
determined by 1D-Noesy NMR, which was used to help to determine the position of anomeric 
proton of all the other products in 
1
H-NMR. The methyl glycoside was then hydrolyzed by 
stirring in an 80% acetic aqueous solution for two days at 115
o
C, affording compound 41 (75%, 
α;β, 1:1.5). The anomeric ratio was determined by 1H-NMR (H-1α, 5.02 ppm, d, J1,OH 8.5 Hz; H-
1β, 5.40 ppm J1,2 4.5Hz, J1,OH 8.0 Hz) (Scheme 2.6).
 
 
 
Scheme 2.6. The synthesis of the arabinose donor.
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Purification of methyl glycoside 30 by flash chromatography had to be repeated three times in 
order to obtain the pure compound. An alternative strategy was therefore investigated in order to 
increase the efficiency of the synthetic route to 41 (Scheme 2.7).
54
  
In this alternative synthetic route, compound 29 was initially perbenzoylated. Because methyl-
2,3,5-tri-O-benzoyl-α-D-arabinofuranoside 42 is a crystalline solid, it could be fully purified 
easily by crystallization (the β-anomer of 42 is an oil).49 However the crystallization of 
compound 42 was not as straight forward as described in the literature. Because the reaction was 
done on a large scale, during the crystallization some of the β-anomer co-crystallized, resulting 
in yellow colored crystal. A second recrystallization was performed to obtain pure methyl 2,3,5-
tri-O-benzoyl-α-D-arabinofuranoside 42 (yield 40%). Deprotection of 42 in a solution of NaOMe 
and MeOH was complete in 1 hour, and afforded methyl-α-D-arabinofuranoside 43 in a good 
yield (98%). It was expected that with pure methyl-α-D-arabinofuranoside 43, the benzylation 
reaction would afford a cleaner product.  The benzylation of 43 was in fact cleaner as shown by 
t.l.c., and a single purification by flash chromatography yielded the pure product 44 in 88%. The 
synthesis of 41 from 44 followed the same procedure as that described in the first synthetic route 
(75%). Compare the two synthetic routes the earlier method produced a higher yield, whilst the 
later method consumed less time and effort. 
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Scheme 2.7. The alternative synthetic pathway for synthesizing 2,3,5-tri-O-benzyl-α,β-D-arabinofuranose 
41.
 
 
2.3.3 Synthesis of Sulfamide Acceptors  
The sulfamide acceptors were synthesized following a published  procedure involving the 
commercially available chlorosulfonyl isocyanate 45 (1.0 eqv.), and a variety of amines 
incorporating different side chains (Scheme 2.8).
51
 In the first step, tert-butyl alcohol (t-BuOH) 
was used to form the NH-Boc protected intermediate. Amines 46a - f were then added into the 
same reaction vessel to afford compounds 47 - 52.  The yields for these steps were consistently 
moderate (50-58%), probably due to the fact that the starting material 45 is extremely reactive 
and moisture sensitive. Pure compound 52 was impossible to obtain even after several 
purification steps. However it was proved that the impurities did not affect the later reactions. 
The NHBoc protected sulfamides 47 - 52 were deprotected by treatment with trifluoroacetic acid 
(5.0 eqv.) to give sulfamides 53 - 58 in excellent yields (70-88%). Amine 2-(2-(2-
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(benzyloxy)ethoxy)ethoxy)ethylamine 46f was synthesized by monobenzylation of  
commercially available TEG 46g in four steps (Scheme 2.9). 
 
Scheme 2.8. The synthesis of sulfamide acceptors. 
 
2.3.4 The Synthesis of 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethylamine 46f 
In the first step one of the hydroxyl groups of TEG 46g was protected as a benzyl ether following 
a published method.
55
 The Ag2O required in this step was freshly made, which was also 
commercially available. Although the literature stated the usage of freshly made Ag2O was 
important, it was found that using commercial Ag2O produced 46h in a similar yield (70%). In 
the second step, the free hydroxyl group of 46h was converted into a good leaving group 
(mesylate) using mesyl chloride (2.0 eqv.) in the presence of triethylamine (1.5 eqv.) in dry 
DCM.
56
 The reaction was completed in just two hours. Compound 46i was then used directly in 
the next step without further purification. In the next step, the mesylate was replaced by an azide 
by the treatment with sodium azide in DMF to give 46j (70%). In the final step, the azide of 46j 
was reduced to an amine using triphenylphosphine in DCM to afford 46f 2-(2-(2-
(benzyloxy)ethoxy)ethoxy)ethylamine. Initial attempts to purify 46f by flash chromatography 
used WIPE (water, isopropane, ethyl acetate) and acetic acid of a ratio 10:60:30:2 as the eluting 
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solvent, but it was found that compound 46f formed into an acetate salt with acetic acid, which 
affected the later reactions. A different solvent system (ethyl acetate → ethyl acetate: acetone, 
3:2) was then used as eluent for the flash chromatography and compound 46f was finally 
obtained in an excellent yield (85%).   
 
Scheme 2.9. The synthesis of a TEG 46g derived amine 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethylamine 
46f. 
 
2.3.5 Synthesis of Sulfamidoglycosides 
Little work has been reported on the use of sulfamide as an isosteric replacement for the 
phosphate group of DPA for anti-TB drug design. In fact only one example exists in the 
literature concerning about the potential use of sulfamides in anti-TB drug design.
57
 The first 
work done in the group on this topic was by Wilkinson (unpublished work). Initially he 
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attempted to synthesize two sulfamidoglycosides 62 and 63 by the stereoselective 
sulfamidoglycosylation of a conformationally constrained thioglycoside 59
58
 with the sulfamides 
incorporating alkyl chains 60 and 61 (Scheme 2.10).
59,60
 However the stereoselectivity was poor 
(α:β, 1:2 at best) and the yields of this step were moderate (55-76%) even though a variety of 
activation conditions were investigated (Table 2.3). Furthermore, the sulfamidoglycosylation 
employing the thioglycoside 59 was not clean and the product required repeated 
chromatographic purification.  
 
Scheme 2.10. Stereoselective synthesis of glycosyl sulfamides 62, 63 from the conformational 
constrained thioglycoside 59 by Wilkinson. 
 
Entry Conditions 
Acceptor 
(R) 
Yields 
(%) 
1 NIS (1.5 eq.), AgOTf (0.5 eq.), DCM, 4Å MS, -78 ºC  → r.t. C8H17 
55 (α:β, 
1:1.7) 
2 NIS (1.5 eq.), AgOTf (0.5 eq.), DCM, 4Å MS, -78 ºC  → r.t. C8H17 
62 (α:β, 
1:2) 
3 
I2 (1.0 eq.), AgOTf (2.0 eq.), DTBMP (2.0 eq.), 3 Å MS, Et2O, -78 ºC  
→ r.t 
C10H21 
76 (α:β, 
1:1) 
Table 2.3. Attempted stereoselective sulfamidoglycosylation with donor 61, 62 by Wilkinson. 
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Therefore Wilkinson adopted a direct sulfamidoglycosylation method (Scheme 2.11), with which 
he synthesized compounds 62 (87%) and 63 (94%). Compound 62 and 63 were formed as 
mixtures of α- and β-anomers (α:β, 1:1) and they were not separable by flash chromatography at 
this stage. Hydrogenation of 62 and 63 was achieved in a solvent mixture of methanol and acetic 
acid (9:1, v/v) in the presence of Pd-C (10% Pd) under an atmosphere of hydrogen. These 
reactions afforded products that were mixtures of α-and β-anomers which were separable by 
flash chromatography. The β-anomers of 64 and 65 were isolated and purified by flash 
chromatography in good yields (87%-88% based on the β anomer). Compounds 64 and 65 were 
then tested against the growth of M. bovis BCG using the “Alamar Blue” assay, and were both 
found to have an MIC value of 31µg/mL.  
 
Scheme 2.11. The synthesis of 64, 65 by direct sulfamidoglycosylation by Wilkinson. 
 
Following the success achieved by Wilkinson for the synthesis of the two β-sulfamidoglycosides, 
a new series of β-sulfamidoglycosides from D-arabinose donor 41 and sulfamide acceptors 53 -
58 were attempted to be synthesized by the direct sulfamidoglycosylation method (Scheme 2.12). 
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Scheme 2.12. The synthesis of compounds 72 – 77 by direct sulfamidoglycosylation. 
 
Direct sulfamidoglycosylation proceeded in dry DCM and in the presence of TMSOTf (1.0 eqv) 
and crushed activited 4Å molecular sieves as moisture severely compromised reaction yields 
(mentioned in the unpublished work of Wilkinson). These reactions afforded compounds 66 - 71 
as anomeric mixtures in good yields (70%-80%, α:β, 1:1.3 to 1:2 for compounds 66 - 70, α:β, 
1:20 for compound 71). The anomeric ratios were determined by 
1
H-NMR (H-1α, s; H-1β, d, J1β-
2 4.1 Hz). The α- and β-isomers showed no chromatographic resolution by t.l.c., and thus they 
were not separable by flash chromatography. Compounds 66 - 71 were then deprotected by 
hydrogenation in a solution of methanol and acetic acid (9:1, v/v) in the presence of 10% Pd-C 
(40% by the weight of 66 - 71) or Pd-black (5% by the weight of 66 - 71) under an atmosphere 
of hydrogen. Occasionally the hydrogenation process stopped, and the reaction did not proceed 
any further. In these cases, the reaction mixture was filtered through celite®, concentrated in 
vacuo, and then redissolved in fresh solvent. The hydrogenation reaction was then restarted with 
new reagents and under the same conditions. After deprotection was completed, the pure β-
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anomers 72 - 77 were isolated by flash chromatography in reasonable yields (50%-65%, H-1, d, 
J1-2 ~ 7.0 Hz, J1-NH ~ 10 Hz). 
 
2.3.6 Stereoselective Synthesis of Sulfamidoglycoside from Glycosyl Bromide 
As described earlier, the synthesis of thioglycosides (34a - g) from the glycosyl bromide 33 and 
alkyl thiols in the presence of TTBP were completely stereoselective giving only the β-
anomers.
47
 Thus, the same scheme was tried in order to synthesize sulfamidoglycoside 
stereoselectively  (Scheme 2.13).  
 
Scheme 2.13. The sulfamidoglycosylation from glycosyl bromide 33 and sulfamide acceptor 56. 
 
The synthesis of glycosyl bromide 33 from 2,3,5-tri-O-benzyl-α,β-D-arabinose 31 followed the 
procedure described in the work of Ayers.
47 
Glycosyl bromide 33 was used in the 
sulfamidoglycosylation with the sulfamide acceptor 56 without further purification. However, 
Results and Discussion 
30 
 
after 16 hours, the reaction had not proceeded significantly by t.l.c. and multiple spots were 
shown on the t.l.c. plate. The reaction was worked up and compound 78 was isolated by flash 
chromatography in a very poor yield (10%). 
1
H-NMR analysis showed that compound 78 had 
been formed as a mixture of α- and β-anomers with α-anomer predominating (α:β, 2:1). The 
anomeric ratio was obtained by 
1
H-NMR (H-1β, 5.21 ppm, dd, J1-2 4.5 Hz, J1-NH 10.5 Hz; H-1α, 
5.30 ppm, d, J1-NH 11.5 Hz,). This route was therefore abandoned. 
 
2.4 Biological Testings 
Compounds 72 - 77 were tested by Priya Deri (Hon. 2011) against the growth of M. bovis BCG 
as the model for M. tuberculosis using the “Alamar Blue” assay.61 The MIC values obtained for 
compounds 73 and 74 are shown in Table 2.4. Unfortunately the assays on the rest of the 
compounds had not been completed in time for inclusion in this thesis. 
Compound MIC (µg/mL) 
73 125 
74 31 
 
Table 2.4. The MIC values of compounds 73 and 74 against the growth of M. bovis BCG obtained in the 
“Alamar Blue” assay. 
 
It can be seen that both compounds inhibit bacterial growth. Presumably this is a result of 
inhibition of araTs involved in cell wall biosynthesis, though this last must be confirmed by 
further study.  
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These results go some way to validate the use of the sulfamide group as an isosteric replacement 
for the phosphate in DPA. However even the most active compound is still an order of 
magnitude less active than current front-line anti-TB drugs. 
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2.4 Conclusions and Future Work 
During this research program, six novel sulfamide analogues of DPA were synthesized. Two of 
these sulfamide analogues and the two previously synthesized sulfamide analogues were tested 
against the growth of M. bovis BCG using the “Alamar Blue” assay, and all compounds were 
found to be active.  This project aims to investigate the inhibitory potential of glycosyl 
sulfamides and also the impact of varying the chain length on the inhibitory activities. 
Unfortunately because of the delays in obtaining the assay results for the other four sulfamide 
analogues, we cannot yet conclude as to whether the side chains of the sulfamide analogues play 
an important part in their inhibitory activity.  
Anti-TB drug development based on sulfamides is an exciting new topic. In future research in 
this area, some sulfamide analogues with longer side chains and side chains possessing 
unsaturation could be synthesized to access better mimics of the decaprenol chain in DPA.     
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Chapter 3: Experimental 
3.1 General Experimental 
Solvents and Reagents: All chemicals were purchased from Sigma Aldrich, Merck, BHD, or 
Scharlau. Water was distilled. All other solvents were used as supplied (Analytic or HPLC 
grade) without further purification. TTBP was recrystallised from methanol. „Petrol‟ refers to the 
fraction of light petroleum ether boiling in the range of 40 - 60 °C. Chromatography: Thin 
layer chromatography (t.l.c.) was performed on Merck Kieselgel 60F254 pre-coated aluminum-
backed plates. Visualisation of the plates was achieved using a u. v. lamp (λmax = 365 nm), and 
ammonium molybdate (5% in 2M H2SO4) or sulfuric acid (5% in EtOH) or ninhydrin (0.37% in 
0.5 M acetic acid in n-butanol). Flash chromatography was performed using Merck silica gel 60 
(0.063 - 0.200 mm). Melting Points: Melting points were recorded on an Electrothermal Melting 
Point Apparatus. Temperatures are given in °C. Optical Rotations: Optical rotations were 
measured on a Perkin-Elmer 341 polarimeter with a path length of 1 dm. Concentrations are 
given in g/100 mL. Infrared Spectroscopy: Infrared spectra were recorded on Perkin-Elmer 
Diffuse Reflectance FT-IR spectrophotometer. Peaks are given in cm
-1
. NMR Spectroscopy: 
Proton nuclear magnetic resonance spectra (δH) were recorded on a Varian As500 (500 MHz) 
spectrometer and were calibrated according to the chemical shift of the deuterated solvent stated 
or TMS (0.0 ppm). Carbon nuclear magnetic resonance spectra (δC) were recorded on a Varian 
As500 (125 MHz) spectrometer and were calibrated according to the chemical shift of the 
deuterated solvent stated. All chemical shifts are quoted in ppm and coupling constants (J) in Hz. 
The abbreviations used to denote multiplicities can be found in the Abbreviations section. Mall 
Spectrometry: Low-resolution and high-resolution mass spectra were recorded on a Bruker 
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Maxis micrOTOF (ESI) spectrometer. Biological Test: The “Alamar Blue” assay was performed 
by Priya Deri in Biology Department of the University of Canterbury. 
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3.2 Experimental Methods 
 
methyl-α,β-D-arabinofuranoside 29 
D-arabinose (10.0 g, 66.6 mmol, 1.0 equiv.) was suspended in methanol (195 mL) and stirred 
under nitrogen at room temperature. Acetyl chloride (6.0 mL, 84.0 mmol, 1.3 equiv.) was added 
slowly and the reaction was stirred vigorously for 3 hours. T.l.c. (DCM:MeOH, 4:1) indicated  
formation of two products, a major product methyl-α,β-D-arabinofuranoside (Rf 0.3) and a minor 
product methyl-α,β-D-arabinopyranoside (Rf 0.4) and complete consumption of starting material 
(Rf 0.0). The mixture was neutralized by adding solid K2CO3 (11.2 g, 81.0 mmol), filtered and 
the filtrate was concentrated in vacuo and co-evaporated with toluene (3 x 100 mL) to afford a 
crude mixture of methyl- α,β-D-arabinofuranoside 29 and methyl- α,β-D-arabinopyranoside as a 
brown oil which was used in the next step without further purification.  
 
 
methyl 2,3,5-tri-O-benzyl-α,β-D-arabinofuranoside 30 
A solution of methyl-α,β-D-arabinofuranoside 29 (10.8 g, 66.8 mmol, 1.0 equiv.) in DMF (75 
mL) was added dropwise to a solution of sodium hydride (60% disperse in mineral oil, 11.8 g, 
294.9 mmol, 4.5 equiv.) in DMF (75 mL) under nitrogen. The mixture was stirred vigorously for 
1 hour before the dropwise addition of benzyl bromide (35.3 mL, 297.2 mmol, 4.5 equiv.). The 
mixture was allowed to stir over night. T.l.c. (petrol:ethyl acetate, 7:1) indicated formation of a 
single product (Rf 0.5) and  consumption of starting material (Rf 0.1). The reaction mixture was 
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quenched in ice bath by slow addition of ethanol (60 mL), methanol (60 mL) and water (240 
mL), and concentrated in vacuo. The residue was diluted with diethyl ether (200 mL) and 
washed with brine (3 x 70 mL of a saturated solution). The organic phase was dried (MgSO4), 
filtered and concentrated in vacuo to afford a yellow oil. The residue was purified by flash 
chromatography (petrol:ethyl acetate, 7:1) to afford a mixture of methyl 2,3,5-tri-O-benzyl-α,β-
D-arabinofuranoside 30 (21.7 g, 75%, α:β, 2.8:1) as a clear oil. δH (500 MHz, acetone-d6) 3.29 
(3H, s, alkyl CH3-β), 3.32 (8.4H, s, alkyl CH3-α), 3.61-3.69 (7.6H, m, H-5α, H-5‟α, H-5β, H-
5‟β), 3.96 (2.8H, dd, J2,3 3.0 Hz, J3,4 6.5 Hz, H-3α), 4.03 (2.8H, d, J2,3 2.5 Hz, H-2α), 4.03-4.08 
(3H, m, H-2β, H-3β, H-4β), 4.12-4.16 (2.8H, aq, J 5.5Hz, H-4α), 4.53-4.67 (22.8H, m, PhCH2-α, 
PhCH2-β), 4.89 (1H, d, J1,2 4.0 Hz, H-1β), 4.95 (2.8H, s, H-1α), 7.25-7.40 (57H, m, Ar-H). m/z 
(ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak observed: 457.1984 (100%), peak calculated : 
457.1985. 
 
 
2,3,5-tri-O-benzyl-α,β-D-arabinofuranose 31 
Methyl 2,3,5-tri-O-benzyl-α, β-D-arabinofuranoside 30 (14 g, 32.2 mmol) was dissolved in an 
mixed solvent of water and acetic acid (250 mL, 4:1, v/v). the reaction was stirred at 115℃ for 2 
days. After this time, T.l.c. (petrol:ethyl acetate, 3:1) indicated formation of one product (Rf 0.1)  
and consumption of starting marterial (Rf 0.4). The reaction mixture was poured onto ice-water 
mixture (500 mL) and the mixture was extracted with diethyl ether (3 x 400 mL). The combined 
organic phase was dried (MgSO4), filtered and concentrated in vacuo to afford a yellow oil. The 
residue was purified by flash chromatography (petrol:ethyl acetate, 3:1) to afford a mixture of 
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2,3,5-tri-O-benzyl-α, β-D-arabinofuranoside 31 (9.5 g, 70%, 1:1.5 α:β) as a white solid . δH (500 
MHz, acetone-d6), 3.60-3.66 (5H, m, H-5α, H-5‟α, H-5β, H-5‟β), 4.01- 4.05 (5H, m, H-2α, H-3α, 
H-2β, H-3β), 4.12-4.17 (1.5H, m, H-4β), 4.55-4.73 (16H, m, PhCH2, H-4α), 5.02 (1H, d, J1,OH 
8.5 Hz, H-1α), 5.4 (1.5H, dd, J1,2 4.5Hz, J1,OH 8.0 Hz, H-1β), 7.26-7.35 (37.5H, m, Ar-H). m/z 
(ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak observed: 443.1851 (100%), peak calculated : 
443.1829. 
 
 
acetyl 2,3,5-tri-O-benzyl-α,β-D-arabinofuranoside 32 
2,3,5-Tri-O-benzyl-α,β-D-arabinofuranose 31 (1.5 g, 3.6 mmol) was dissolved in pyridine 
(15mL) and DMAP (44 mg, 0.4 mmol) was added. The solution was stirred under hydrogen at 
0 C and Ac2O (0.7 mL, 7.2 mmol) was added slowly. The reaction was allowed to return to r.t. 
and stirred for 16 h. T,l.c. (petrol:ethyl acetate, 5:1) indicated formation of one product (Rf 0.5) 
and complete consumption of starting material (Rf 0.1). The reaction was cooled to 0°C and 
quenched with EtOH (10 mL). The reaction mixture was concentrated in vacuo and co-
evaporated with toluene (3 x 20 mL). The residue was purified by flash chromatography 
(petrol:ethyl acetate, 5:1) to afford a mixture of acetyl 2,3,5-tri-O-benzyl-α,β-D-
arabinofuranoside 32 (1.5 g, 91%, α:β, 1:5.3) as a clear oil. δH (500 MHz, CHCl3-d) 2.02 (15.9H, 
s, COCH3-β), 2.08 (3H, s, COCH3-α), 3.61-3.62 (10.6H, m, H-5β, H-5‟β), 3.66-3.67 (2H, m, H-
5α, H-5‟α), 4.02 (1H, d, J3,4 5.8 Hz, H-3α), 4.11-4.26 (11.6H, m, H-2α, H-2β, H-3β), 4.20-4.46 
(1H, aq, J 5.1 Hz, 4α), 5.54-5.74 (43.1H, m, PhCH2-α, PhCH2-β, H-4β), 6.31 (1H, s, H-1α), 6.33 
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(5.3H, d, J1,2 4.0  Hz, H-1β), 7.24-7.41 (94.5H, m, Ar-H);  m/z (ESI
+
) species observed (M+Na
+
); 
(M+Na
+
) peak observed: 485.1940 (100%), peak calculated : 485.1935. 
 
 
2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl bromide 33 
Acetyl 2,3,5-tri-O-benzyl-α,β-D-arabinofuranoside 32 (429.2 mg, 1.85 mmol) was dissolved in 
dry DCM (10 mL) and cooled to -40°C under an atmosphere of nitrogen. TMSBr (1.3 mL, 18.5 
mmol) was added, the reaction stirred for 10 min and allowed to return to r.t.. After 10 min t.l.c. 
(petrol:ethyl acetate, 5:1) indicated formation of one major product (Rf 0.1) and complete 
consumption of starting material (Rf 0.5). The reaction mixture was concentrated in vacuo and 
unreacted TMSBr co-evaporated with toluene (3 x 5 mL). This afforded a crude mixture of 2,3,5-
Tri-O-benzyl-α,β-D-arabinofuranosyl bromide 33 (α:β, 7.5:1) as an orange oil, used in the next 
step without further purification. δH  (500 MHz, CHCl3-d) 3.50-3.61 (17H, m, H-5α, H-5‟α, H-
5β, H-5‟β), 3.82-3.88 (7.5H, d, J3,4 5.8 Hz, H-3α), 4.00-4.25 (2H, m, H-2β, H-3β), 4.28-4.66 
(67H, m, H-2α, H-4α, H-4β), 6.41 (7.5H, s, H-1α), 6.52 (1H, d, J1,2 3.0 Hz, H-1β) 7.08-7.28 
(127.5H, m, Ar-H). 
 
 
2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethanol 46h 
Tri(ethylene) glycol (4.8 mL, 36 mmol) was added to a suspension of silver oxide (12.6 g, 54.0 
mmol) in dry DCM (150 mL) under nitrogen. Benzyl bromide (4.8 mL, 39.6 mmol) was then 
added drop-wise at room temperature and the mixture was allowed to stir for 16 hours. T.l.c. 
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(petrol:ethyl acetate, 2:1) indicated formation of product (Rf 0.2) and consumption of starting 
material (Rf 0.0). The reaction mixture was filtered on Celite®, eluting with methanol and 
concentrated in vacuo to afford a yellow oil. The residue was purified by flash chromatography 
(petrol:ethyl acetate, 2:1) to afford product as a clear oil 2-(2-(2-
(benzyloxy)ethoxy)ethoxy)ethanol 46h (6.2 g, 72%). δH (500 MHz, acetone-d6) 2.92 (1H, s, 
OH), 3.50-3.65 (12H, m, CH2), 4.53 (2H, s, Ph-CH2) 7.22-7.38 (5H, m, Ar-H); m/z (ESI
+
) 
species observed (M+Na
+
); (M+Na
+
) peak observed: 263.1260 (70%), peak calculated: 
263.1254. 
 
 
((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)benzene 46j 
Mesylchloride (2.6 mL, 33.7 mmol,) was added dropwise to a solution of 2-(2-(2-
(benzyloxy)ethoxy)ethoxy)ethanol 46h (5.4 g, 22.5 mmol, 1.0) in dry DCM (30 ml) at 0ºC under 
nitrogen. The reaction was allowed to return to room temperature and stirred for 2 hours. T.l.c. 
(petrol:ethyl acetate, 1:1) indicated formation of a single product (Rf 0.5) and complete 
consumption of starting marterial (Rf 0.2). The reaction was quenched by the addition of 
methanol (20 mL). The reaction mixture was concentrated in vacuo. The residue was dissolved 
in DMF (50 mL) and stirred at room temperature under nitrogen. Sodium azide (1.46 g, 22.5 
mmol) was then added into the solution. The reaction was heated up to 65 ˚C and allowed to stir 
at 65ºC for 16 hours. T.l.c. (petrol:ethyl acetate, 2:1) indicated formation of a single product (Rf 
0.4) and consumption of starting material (Rf 0.3). The reaction mixture was diluted with water 
(30 ml) and extracted with ether (3 x 50 mL). The combined extracts were washed with brine (3 
x 30 mL of a saturated solution), dried (MgSO4), filtered and concentrated in vacuo to afford a 
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yellow oil. The residue was purified by flash chromatography (petrol:ethyl acetate, 5:1) to afford 
((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)benzene 46j (4.2 g, 71%)  as a clear oil. δH (500 
MHz, CDCl3)  3.37 (2H, t, J 5.0 Hz, CH2), 3.63 - 3.71 (10H, m, CH2), 4.57 (2H, s, Ph-CH2), 7.18 
- 7.44 (5H, m, Ar-H); m/z (ES
+
) 288.1323 (M+Na
+
, 100%); HRMS (ES
+
) calculated for 
C13H19N3NaO3 (M+Na
+
) 288.1323. Found 288.1319. 
 
 
2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethanamine 46f 
Triphenylphosphine (8.8 g, 34.0 mmol) and water (0.6 mL, 34.0 mmol) was added to a solution 
of of ((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)benzene 46j (4 g, 17.0 mmol)  in THF (~ 50 
mL) under nitrogen. The reaction was allowed to stir under nitrogen for 16 hours. T.l.c. 
(petrol:ethyl acetate, 2:1) indicated formation of a single product (Rf 0.0) and consumption of 
starting material (Rf 0.7). The reaction mixture was concentrated in vacuo to afford a yellow oil. 
The residue was purified by gradient flash chromatography (ethyl acetate → ethyl 
acetate:acetone, 3:2) to afford 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethanamine 46f (3.4 g, 85.0%) 
as a clear oil. δH (500 MHz, methanol-d4)  2.76 (2H, t, J 5.32 Hz, CH2NH2), 3.51 (2H, t, J 5.0 
Hz, CH2), 3.58 - 3.73 (8H, m, CH2), 4.55 (2H, s, Ar-CH2), 7.22 - 7.43 (5H, m, Ar-H); m/z (ES
+
) 
240.1600 (M+H
+
, 100%); 262.1419 (M+Na
+
, 100%); HRMS (ES
+
) calculated for C13H22NO3 
(M+H
+
) 240.1600. Found 240.1594. Calculated for C13H21N3NaO3 (M+Na
+
) 262.1419. Found 
262.1414. 
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N-(hexyl)-N’-(tert-butoxycarbonyl)sulfamide 47 
A stirred solution of chlorosulfonyl isocyanate (1.5 mL, 17.1 mmol, 1.0 equiv.) in dry DCM (20 
mL) was cooled to 0˚C under nitrogen, and tert-butyl alcohol (2.3 mL, 24.0 mmol, 1.4 equiv.) 
was added drop-wise. The solution was stirred for a further 30 minutes at 0 ˚C. A solution of 
hexylamine (2.3 mL, 17.1 mmol, 1.0 equiv.) and dry triethylamine (2.7 mL, 18.8 mmol, 1.1 
equiv.) in dry DCM (20 mL) was then added dropwise. The reaction mixture was allowed to 
return to room temperature and stirred for 16 hours. T.l.c. (DCM, charring with ninhydrin) 
indicated formation of a single product (Rf ~ 0.5, streaking) and consumption of starting material 
(Rf ~ 0.1, streaking). The reaction mixture was diluted with DCM (50 mL), washed with 
saturated aqueous NaHCO3 solution (3 x 50 mL) and brine (3 x 50 mL of a saturated solution). 
The organic layer was dried (MgSO4), filtered and concentrated in vacuo to afford a yellow oil. 
The residue was purified by flash chromatography (DCM) to afford N-(hexyl)-N‟-(tert-
butoxycarbonyl)sulfamide 47 (2.7 g, 58.0%) as a white solid, m.p. 98-102 ºC (ethyl 
acetate/petrol. υmax (diffraction) 3300 (s, N-H),  1709 (s, C=O), 1353 (s, S=O), 1170 (s, S=O) cm
-
1;  δH (500 MHz, acetone-d6) 0.89 (3H, t, J 7.2 Hz, CH3), 1.30-1.31 (4H, m, CH2CH2CH3), 1.36-
1.39 (2H, m, NHCH2CH2CH2 ), 1.46 (9H, s, tert-Bu CH3), 1.60 (2H, quin, J 7.6 Hz, 
NHCH2CH2), 3.05 (2H, q, J 7.0 Hz, NHCH2); δC (126 MHz, acetone-d6) 13.6 (CH3), 22.5 (CH2), 
26.4 (CH2), 27.5 (tert-Bu CH3), 29.2 (CH2), 31.5 (CH2), 43.7 (CH2), 81.7 (tert-Bu C), 150.9 
(O=C); m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak observed: 303.1349 (100%), peak 
calculated : 303.1354. 
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N-(octyl)-N’-(tert-butoxycarbonyl)sulfamide 48 
A stirred solution of chlorosulfonyl isocyanate (1 mL, 11.4 mmol) in dry DCM (12 mL) was 
cooled to 0˚C under nitrogen, and tert-butyl alcohol (1.5 mL, 16.0 mmol) was added drop-wise. 
The solution was stirred for a further 30 minutes at 0 ˚C. A solution of octylamine (1.9 mL, 11.4 
mmol) and dry triethylamine (1.8 mL, 12.5 mmol) in dry DCM (12 mL) was then added 
dropwise. The reaction mixture was allowed to return to room temperature and stirred for 16 
hours. T.l.c. (DCM:MeOH, 30:1, charring with ninhydrin) indicated formation of a single 
product (Rf  ~ 0.8, streaking) and consumption of starting material (Rf ~ 0.2, streaking). The 
reaction mixture was diluted with DCM (50 mL), washed with saturated aqueous NaHCO3 
solution (3 x 50 mL) and brine (3 x 50 mL of a saturated solution). The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo to afford a yellow oil. The residue was purified by 
gradient flash chromatography (DCM → DCM:methanol, 20:1) to afford N-(octyl)-N‟-(tert-
butoxycarbonyl)sulfamide 48 (1.8 g, 51.6%) as a white solid. m.p. 102 ºC (ethyl actate/petrol). 
υmax (diffraction) 3334 (w, N-H) 3292 (m, N-H), 1709 (s, C=O), 1350 (s, S=O), 1165 (s, S=O) 
cm
-1; δH (500 MHz, acetone-d6) 0.88 (3 H, t, J=6.42 Hz), 1.28-1.33 (10 H, m, CH2), 1.47 (9 H, s, 
tert-Bu CH3), 1.56 - 1.64 (2 H, m, CH2CH2NH), 3.03 - 3.08 (2 H, t, J=7.0 Hz, CH2NH) 6.38 (1H, 
br. s, CH2NH); δc (126 MHz, acetone-d6) 13.7 (CH3), 22.6 (CH2), 26.7 (CH2), 27.5 (tert-Bu 
CH3), 29.2 (CH2), 29.2 (CH2), 29.3 (CH2), 31.9 (CH2), 43.7 (CH2NH); m/z (ESI
+
) 331.1669 
(M+Na
+
, 100%); HRMS (ESI
+
) calculated for C13H28N2NaO4S  (M+Na
+
) 331.1669. Found 
331.1662. 
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N-(decyl)-N’-(tert-butoxycarbonyl)sulfamide 49 
A stirred solution of chlorosulfonyl isocyanate (2.0 mL, 22.8 mmol) in dry DCM (12 mL) was 
cooled to 0˚C under nitrogen and tert-butyl alcohol (3.0 mL, 16.0 mmol) was added drop-wise. 
The solution was stirred for a further 30 minutes at 0 ˚C. A solution of decylamine (4.8 mL, 22.8 
mmol) and dry triethylamine (3.6 mL, 25.1 mmol) in dry DCM (12 mL) was then added 
dropwise. The reaction mixture was allowed to return to room temperature and stirred for 16 
hours. T.l.c. ( DCM:MeOH, 30:1, charring with ninhydrin) indicated formation of a single 
product (Rf  ~ 0.80 streaking) and consumption of starting material (Rf ~ 0.20 streaking). The 
reaction mixture was diluted with DCM (100 mL), washed with saturated aqueous NaHCO3 
solution (3 x 70 mL) and brine (3 x 70 mL of a saturated solution). The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo to afford a yellow oil. The residue was purified by 
gradient flash column chromatography (DCM → DCM:methanol, 20:1) to afford N-(decyl)-N‟-
(tert-butoxycarbonyl)sulfamide 49 (3.8 g, 50%) as a white solid, m.p. 97-98 ˚C (ethyl 
acetate/petrol). υmax (diffraction) 3327(w, N-H), 3289 (m, N-H), 1710 (s, C=O), 1350 (s, S=O), 
1150 (s, S=O) cm
-1; δH (500 Hz, CDCl3) 0.88 (3H, t, J=6.97 Hz, CH3), 1.19 - 1.39 (14H, m, 
CH2), 1.50 (9H, s, tert-Bu CH3), 1.54 - 1.64 (2H, m, CH2CH2NH), 3.06 (2H, q, J=6.72 Hz, 
CH2NH), 5.03 (1H, t, J C (126 MHz, acetone) 13.7 (CH3), 
22.7 (CH2), 26.7 (CH2) 27.5 (tert-Bu CH3 ),  29.8 (CH2), 30.0 (CH2) 30.2 (CH2), 30.3 (CH2), 
30.3 (CH2), 40.7 (CH2), 81.7 (tert-Bu C), 150.9 (C=O); m/z (ESI
+
) 359.1978 (M+Na
+
, 100%); 
HRMS (ESI
+
) calculated for C15H32N2NaO4S  (M+Na
+
) 359.1978. Found 359.1975. 
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N-(dodecyl)-N’-(tert-butoxycarbonyl)sulfamide 50 
A stirred solution of chlorosulfonyl isocyanate (1.0 ml, 11.4 mmol) in dry DCM (15 mL) was 
cooled to 0˚C under nitrogen, and tert-butyl alcohol (1.5 mL, 16.0 mmol) was added drop-wise. 
The solution was stirred for a further 30 minutes at 0 ˚C. A solution of dodecylamine (2.2 g, 11.4 
mmol) and dry triethylamine (1.8 mL, 12.5 mmol) in dry DCM (12 mL) was then added 
dropwise. The reaction mixture was allowed to return to room temperature and stirred for 16 
hours. T.l.c. (DCM, charring with ninhydrin) indicated formation of a single product (Rf ~ 0.3, 
streaking) and consumption of starting material (Rf ~ 0.0). The reaction mixture was diluted with 
DCM (50 mL), washed with saturated aqueous NaHCO3 solution (3 x 50 mL) and brine (3 x 50 
mL of a saturated solution). The organic layer was dried (MgSO4), filtered and concentrated in 
vacuo to afford a yellow oil. The residue was purified by gradient flash chromatography (DCM 
→ DCM:methanol, 30:1) to afford N-(dodecyl)-N‟-(tert-butoxycarbonyl) sulfamide 50 (2.2 g, 
52%) as a white solid, m.p. 91-93 ºC (petrol/ethyl acetate). υmax (diffraction) 3325 (w, N-H), 
3277 (m, N-H), 1710 (w, C=O), 1350 (s, S=O), 1150 (s, S=O) cm
-1; δH (500 MHz, chloroform-d) 
0.88 (3H, t, J 7.0 Hz, CH3), 1.25-1.34 (22H, m, CH2), 1.45 (9H, s, tert-Bu CH3), 1.53-1.58 (2H, 
m, NHCH2CH2), 3.05-3.06 (2H, m, NHCH2), 5.09 (1H, br. s, NH); δC (500 MHz, chloroform-d) 
14.1 (CH3), 22.7 (CH2), 26.6 (CH2), 28.0 (tert-Bu CH3), 29.0 (CH2), 29.1 (CH2), 29.4 (CH2), 
29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2), 29.7 (CH2), 31.9 (CH2), 43.9 
(NHCH2), 83.8 (tert-Bu C), 150.2 (CO); m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak 
observed: 415.2601 (66.5%), peak calculated: 415.2601. 
 
Experimental 
45 
 
 
N-(tetradecyl)-N’-(tert-butoxycarbonyl)sulfamide 51 
A stirred solution of chlorosulfonyl isocyanate (1.0 ml, 11.4 mmol) in dry DCM (10 mL) was 
cooled to 0˚C under nitrogen, and tert-butyl alcohol (1.5 mL, 16.0 mmol, 1.4 equiv.) was added 
drop-wise. The solution was stirred for a further 30 minutes at 0 ˚C. A solution of dodecylamine 
(2.6 g, 11.4 mmol) and dry triethylamine (1.8 mL, 12.5 mmol) in dry DCM (10 mL) was then 
added dropwise. The reaction mixture was allowed to return to room temperature and stirred for 
16 hours. T.l.c. (DCM, charring with ninhydrin) indicated formation of a single product (Rf ~ 
0.3, streaking) and consumption of starting material (Rf ~ 0.0). The reaction mixture was diluted 
with DCM (50 mL), washed with saturated aqueous NaHCO3 solution (3 x 50 mL) and brine (3 x 
50 mL of a saturated solution). The organic layer was dried (MgSO4), filtered and concentrated 
in vacuo to afford a yellow oil. The residue was purified by flash chromatography (DCM) to 
afford N-(tetradecyl)-N‟-(tert-butoxycarbonyl) sulfamide 51 (1.9 g, 50%) as a white solid, m.p. 
98-100 ºC (petrol/ethyl acetate). υmax (diffraction) 3286 (m, N-H), 1714 (s, C=O), 1348 (s, S=O), 
1150 (s, S=O) cm
-1; δH (500 MHz, chloroform-d) 0.88 (3H, t, J 7.0 Hz, CH3), 1.25-1.34 (22H, m, 
CH2), 1.54-1.58 (2H, m, NHCH2CH2), 3.04-3.06 (2H, m, NHCH2), 5.09 (1H, br. s, NH); δC (500 
MHz, chloroform-d) 14.1 (CH3), 22.7 (CH2), 26.6 (CH2), 28.0 (tert-Bu CH3), 29.0 (CH2), 29.1 
(CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.6 (CH2), 29.7 (CH2), 29.7 (CH2), 31.9 (CH2), 43.9 
(NHCH2), 83.8 (tert-Bu C), 150.2 (CO); m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak 
observed: 415.2618 (65.5%), peak calculated: 415.2601. 
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N-(2-(2-(2-(benzyloxyethoxy)ethoxy)ethyl-N’-(tert-butoxycarbonyl)sulfamide 52 
A stirred solution of chlorosulfonyl isocyanate (1.4 mL, 16.3 mmol) in dry DCM (15 mL) was 
cooled to 0˚C under nitrogen and tert-butyl alcohol (2.1 mL, 22.8 mmol) was added drop-wise. 
The solution was stirred for a further 30 minutes at 0 ˚C. A solution of 2-(2-(2-
(benzyloxy)ethoxy)ethoxy)ethanamine 46f (3.9 g, 16.3 mmol) and dry triethylamine (2.5 mL, 
17.9 mmol) in dry DCM (20 mL) was then added dropwise. The reaction mixture was allowed to 
return to room temperature and stirred for 16 hours. T.l.c. (DCM:MeOH, 20:1, charring with 
ninhydrin) indicated formation of a major product (Rf  ~ 0.4 streaking) and consumption of 
starting material (Rf ~ 0.1 streaking). The reaction mixture was diluted with DCM (25 mL), 
washed with saturated aqueous NaHCO3 solution (3 x 25 mL) and brine (3 x 25 mL of a 
saturated solution). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to 
afford a yellow oil. The residue was purified by gradient flash column chromatography (DCM → 
DCM:methanol, 40:1) to afford N-benzyloxytriethoxy-N’-(tert-butoxycarbonyl) sulfamide 52 
(3.7 g, 55%) as a clear oil. υmax (diffraction) 3293 (m, N-H), 1715 (s, C=O), 1150 (s, S=O) cm
-1
; 
δH (500 MHz, methanol-d4) 1.44 - 1.54 (9 H, m, tert-Bu CH3), 3.19 (1 H, t, J 5.30 Hz, NH2CH2), 
3.53 - 3.71 (8 H, m, CH2), 4.10 (1 H, t, J 5.30 Hz, NH2 CH2CH2 ), 4.56 (2 H, s, Ar-CH2), 7.22 - 
7.43 (5 H, m, Ar); δC (126 MHz) 28.2 (tert-Bu CH3), 44.2 (CH2), 69.9 (CH2), 70.4 (CH2), 70.9 
(CH2), 71.2 (CH2), 73.4 (CH2), 82.6 (tert-Bu C), 128.1 (Ar-C), 128.4 (Ar-C), 129.0 (Ar-C), 
139.8 (Ar-C), 151.7 (CO); m/z (ES
+
) 441.1665 (M+Na, 100%); HRMS (ES
+
) calculated for 
C18H30N2NaO7S  (M+Na
+
) 441.1665. Found 441.1666. 
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N-(hexyl)-sulfamide 53 
Trifluoroacetic acid (2.0 mL, 25.0 mmol) was added to a solution of N-(Hexyl)-N‟-(tert-
butoxycarbonyl)sulfamide 47 (1.4 g, 5.0 mmol) in DCM (40 mL). The solution was stirred at 
room temperature for 16 hours. T.l.c. (petrol:ethyl acetate, 3:1, charring with ninhydrin) 
indicated formation of a major product (Rf  ~ 0.6 streaking) and consumption of starting 
marterial (Rf  ~ 0.2 streaking). The reaction mixture was concentrated in vacuo to afford a yellow 
oil.  The residue was purified by flash chromatography (petrol:ethyl acetate, 3:1) to afford N-
(hexyl)-sulfamide 53 (0.6 g, 70%) as a white solid, m.p. 76-77 ºC (ethyl acetate/petrol). υmax 
(diffraction) 3331 (w, N-H), 3289 (m, N-H), 1357 (s, S=O), 1130 (s, S=O); δH (500 MHz, 
acetone-d6) 0.89 (3H, t, J 0.7 Hz, CH3), 1.28-1.40 (6H, m, CH2), 1.55-1.60 (2H, m, NHCH2CH2), 
3.03-3.07 (2H, m, NHCH2), 5.59 (1H, br. s, NH), 5.81 (2H, s, NH2); δC (500 MHz, acetone-d6) 
13.6 (CH3), 22.6 (CH2), 26.6 (CH2), 29.6 (CH2), 31.6 (CH2), 43.4 (NHCH2); m/z (ESI
+
) species 
observed (M+Na
+
); (M+Na
+
) peak observed: 203.0833 (74.0%), peak calculated : 203.0825. 
 
 
N-(octyl)-sulfamide 54 
Trifluoroacetic acid (1.8 mL, 23.0 mmol) was added to a solution of N-(Octyl)-N‟-(tert-
butoxycarbonyl)sulfamide 48 (1.0 g, 4.6 mmol) in DCM (16 mL). The solution was stirred at 
room temperature for 16 hours. T.l.c. (DCM:MeOH, 30:1, charring with ninhydrin) indicated 
formation of a single product (Rf  ~ 0.3 streaking) and consumption of starting marterial (Rf  ~ 
0.8 streaking). The reaction mixture was concentrated in vacuo to afford a yellow oil.  The 
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residue was purified by flash chromatography (petrol:ethyl acetate, 3:1) to afford N-(octyl)-
sulfamide 54 (0.7 g, 72%) as a white solid. m.p. 66-68 ºC (ether). υmax (diffraction) 3330 (w, N-
H), 3281 (w, N-H), 1350 (w, S=O), 1141 (s, S=O); δH (500 MHz, acetone-d6) 0.88 (3H, t, J 
6.7Hz, CH3), 1.29-1.39 (10H, m, CH2), 1.50-1.61 (2H, m, CH2CH2NH), 3.03-3.08 (2H, m, 
CH2NH), 5.59 (1H, br. s, CH2NH), 5.82 (2H, s, NH2); δC (126 MHz, acetone-d6) 13.7 (CH3), 
22.7 (CH2), 26.9 (CH2), 28.9 (CH2), 29.4 (CH2) 29.6 (CH2), 29.6 (CH2), 43.4 (CH2NH); m/z 
(ESI
+
) 231.1137 (M+Na
+
, 100%); HRMS (ESI
+
) calculated for C8H20N2NaO2S  (M+Na
+
) 
231.1137. Found 231.1138. 
 
 
N-decyl sulfamide 55 
Trifluoroacetic acid (3 mL, 38.6 mmol) was added to a solution of N-(Decyl)-N‟-(tert-
butoxycarbonyl)sulfamide 49 (2.6 g, 7.7 mmol) in DCM (100 mL). The solution was stirred at 
room temperature for 16 hours. T.l.c. (DCM:MeOH, 20:1, charring with ninhydrin) indicated 
formation of a single product (Rf  ~ 0.3 streaking) and consumption of starting marterial (Rf  ~ 
0.7 streaking). The reaction mixture was concentrated in vacuo to afford a yellow oil.  The 
residue was purified by flash chromatography (petrol:ethyl acetate, 3:1) to afford N-decyl 
sulfamide 55 (1.3 g, 72%) as a white solid, m.p. 75-76˚C (ethyl acetate/petrol). υmax (diffration) 
3330 (w, N-H), 3283 (w, NH), 1345 (w, S=O)  1135 (w, S=O) cm
-1; δH (500MHz ,acetone-d6) 
0.88 (3H, t, J=6.60 Hz, CH3), 1.18 - 1.47 (14H, m, CH2), 1.58 (2H, m, CH2CH2NH), 3.07 (2H, q, 
J=6.97 Hz, CH2NH ), 5.59 (1H, br. s. CH2NH), 5.82 (2H, br. s. NH2); δC (126 MHz, acetone-d6) 
13.7 (CH3), 22.7 (CH2), 26.9 (CH2), 28.7 (CH2), 29.4 (CH2),  29.4 (CH2), 29.6 (CH2), 29.6 
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(CH2), 29.7 (CH2), 31.9 (CH2), 43.4 (CH2); m/z (ESI
+
) 259.1445 (M+Na
+
, 100%); HRMS (ESI
+
) 
calculated for C10H24N2NaO2S; (M+Na
+
) 259.1445. Found 259.1451. 
 
 
N-dodecyl sulfamide 56 
Trifluoroacetic acid (1.9 mL, 24.7 mmol) was added to a solution of N-(Dodecyl)-N‟-(tert-
butoxycarbonyl)sulfamide 50 (1.8 g, 4.9 mmol) in DCM (80 mL). The solution was stirred at 
room temperature for 16 hours. T.l.c. (petrol:ethyl acetate, 3:1, charring with ninhydrin) 
indicated formation of a single product (Rf  ~ 0.1 streaking) and consumption of starting 
marterial (Rf  ~ 0.5 streaking). The reaction mixture was concentrated in vacuo to afford a yellow 
oil.  The residue was purified by flash chromatography (petrol:ethyl acetate, 3:1) to afford N-
dodecyl sulfamide 56 (1.0 g, 78%) as a white solid, m.p. 84-88˚C (ethyl acetate/petrol). υmax 
(diffration) 3338 (w, N-H), 3278 (w, NH), 1345 (w, S=O)  1136 (w, S=O) cm
-1
;  δH (500 MHz, 
acetone-d6) 0.88 (3H, t, J 7.3 Hz, CH3), 1.29-1.37 (18H, m, CH2), 1.57-1.58 (2H, m, 
NHCH2CH2), 3.04-3.05 (2H, m, NHCH2), 5.58 (1H, br s, CH2NH), 5.80 (2H, br s, NH2); δC (500 
MHz, acetone-d6) 14.4 (CH3), 23.3 (CH2), 27.6 (CH2), 30.1 (CH2), 30.1 (CH2), 30.3 (CH2), 30.3 
(CH2), 30.4 (CH2), 30.4 (CH2), 32.6 (CH2), 44.1 (CH2);  m/z (ESI
+
) species observed (M+Na
+
); 
(M+Na
+
) peak observed: 287.1760 (100%), peak calculated: 287.1764. 
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N-tetradecyl sulfamide 57 
Trifluoroacetic acid (1.9 mL, 24.7 mmol) was added to a solution of N-(Tetradecyl)-N‟-(tert-
butoxycarbonyl)sulfamide 51 (2.6 g, 6.6 mmol) in DCM (50 mL). The solution was stirred at 
room temperature for 16 hours. T.l.c. (petrol:ethyl acetate, 3:1, charring with ninhydrin) 
indicated formation of a single product (Rf  ~ 0.1 streaking) and consumption of starting 
marterial (Rf  ~ 0.7 streaking). The reaction mixture was concentrated in vacuo to afford a yellow 
oil.  The residue was purified by flash column chromatography (petrol:ethyl acetate, 3:1) to 
afford N-tetradecyl sulfamide 57 (1.4 g, 70%) as a white solid, m.p. 93-95˚C (ethyl 
acetate/petrol). υmax (thin film) 3330 (w, N-H), 3276 (m, NH), 1340 (w, S=O)  1134 (m, S=O) 
cm
-1δH (500 MHz, methanol-d4) 0.90 (3H, t, J 7.3 Hz, CH3), 1.29-1.37 (22H, m, CH2), 1.55 (2H, 
quin., J 7.0 Hz, NHCH2CH2), 3.01 (2H, t, J 7.2 Hz, NHCH2); δC (126 MHz, methanol-d4) 14.4 
(CH3), 23.7 (CH2), 27.9 (CH2), 30.4 (CH2), 30.5 (CH2), 30.6 (CH2), 30.7 (CH2), 30.7 (CH2), 30.8 
(CH2), 30.8 (CH2), 33.1 (CH2), 44.3 (CH2); m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) 
peak observed: 315.2077 (100%), peak calculated: 315.2077. 
 
 
N-((2-(2-(2-(benzyloxyethoxy)ethoxy)ethyl)-sulfamide 58 
trifluoroacetic acid (1.7 mL, 21.5 mmol) was added to a solution of N-(2-(2-(2-
(benzyloxyethoxy)ethoxy)ethyl- N‟-(tert-butoxycarbonyl)sulfamide 52  (1.8 g, 4.3 mmol) in 
DCM (30 mL). The solution was stirred at room temperature for 16 hours. T.l.c. (ethyl acetate : 
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petrol, 2:1, charring with ninhydrin) indicated formation of a single product (Rf 0.2) and 
consumption of starting marterial (Rf 0.0). The reaction mixture was concentrated in vacuo to 
afford a yellow oil.  The residue was purified by flash column chromatography (ethyl acetate : 
petrol, 2:1) to afford  N-((2-(2-(2-(benzyloxyethoxy)ethoxy)ethyl)-sulfamide 58 (1.0 g, 73%)  as 
a clear oil. υmax (thin film) 3277 (m, NH), 1335 (w, S=O)  1132 (w, S=O) cm
-1
;
 δH (500 MHz, 
methanol-d4) 3.21 (2H, t, J 5.00 Hz, CH2), 3.56 - 3.71 (10H, m, CH2), 4.54 (2H, s, CH2-Ar), 7.18 
- 7.41 (5H, m, Ar-H); δC (126 MHz) 49.4 (CH2), 69.3 (CH2), 69.9 (CH2), 70.0 (CH2), 70.1 (CH2), 
70.2 (CH2), 73.0 (CH2), 127.5 (Ar-C), 127.8 (Ar-C), 128.2 (Ar-C), 138.4 (Ar-C); m/z (ES
+
) 
341.1141 (M+Na, 100%); HRMS (ES
+
) calculated for C13H22N2NaO5S  (M+Na
+
) 341.1141. 
Found 341.1142. 
 
 
N-hexyl-N’-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 66 
2,3,5-Tri-O-benzyl-α,β-D-arabinofuranose 31 (1.3 g, 3.0 mmol), N-(Hexyl)-sulfamide 53 in dry 
DCM (50 mL) stirred at room temperature under nitrogen. TMSOTF (0.6 mL, 3.3 mmol) was 
added drop-wise and the mixture was allowed to stir for 16 hours. T.l.c. (petrol:ethyl acetate, 5:1) 
indicated formation of a single product (Rf 0.3) and the consumption of starting material (Rf 0.1) 
. The reaction was neutralized by the drop-wise addition of excess triethylamine (~ 1.2 mL). The 
reaction mixture was filtered on celite®, eluting with ethyl acetate and concentrated in vavuo to 
afford a yellow oil. The residue was purified by flash chromatography (petrol:ethyl acetate, 8:1) 
to afford N-hexyl-N‟-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl) sulfamide 66 (1.2 g, 70%, α:β, 
1:2) as a waxy solid. υmax (thin film) 3264 (w, N-H), 3289 (m, N-H), 1350 (w, S=O), 1158 (w, 
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S=O) cm
-1; δH (500 MHz, chloroform-d) 0.85-0.88 (9H, m, CH3-α, CH3-β), 1.22-1.32 (18H, m, 
CH2-α, CH2-β), 1.45-1.54 (6H, m, NHCH2CH2α, NHCH2CH2β), 2.97-3.05 (6H, m, NHCH2α, 
NHCH2β), 3.46 (2H, dd, J5-5‟ 9.6 Hz, J5-4 7.5 Hz, H-5β), 3.50-3.52 (2H, m, H-5α, H-5‟α), 3.56 
(2H, dd, J5‟-5 9.7 Hz, J5‟-4 5.9 Hz, CH-5‟β), 3.93-4.06 (6H, m, H-3α, H-3β, H-2α, H-2β), 4.08-
4.14 (2H, m, H-4β), 4.16-4.20 (1H, m, NH2α), 4.22-4.26 (2H, m, NH2β), 4.30-4.36 (1H, m, H-
4α), 4.40-4.60 (18H, m, Ph-CH2), 5.36 (1.0H, dd, J1-NH 10.3 Hz, J1,2 4.4 Hz, H-1α), 5.41 (2H, d, 
J1-NH 10.8 Hz, H-1β), 5.55 (1H, d, JNH-1 10.3 Hz, NH-α), 5.59 (2H, JNH-1 10.8 Hz, NH-β), 7.22-
7.34 (35.5H, m, Ar-H); δC (500 MHz, chloroform-d) 14.0 (CH3), 22.5 (CH2), 26.4 (CH2), 29.4 
(CH2), 31.4 (CH2), 43.4 (CH2), 43.5 (CH2), 71.8 (CH2), 71.9 (CH2), 72.3 (CH2), 73.3 (CH2), 80.8 
(CH), 81.2 (CH), 81.8 (CH), 82.3 (CH), 83.3 (CH), 84.3 (CH), 84.7 (CH), 88.2 (CH), 127.7-
138.0 (Ph-C); m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak observed: 605.2656 (100%), 
peak calculated:605.2656. 
 
 
N-octyl-N’-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 67 
2,3,5-Tri-O-α,β-D-benzylarabinofuranose 31 (0.7 g, 1.7 mmol), N-(octyl)-sulfamide 54 (354 mg, 
1.7 mmol) and crushed, activated 3Å molecular sieves (~ 400 mg) were suspended in dry DCM 
(20 mL) stirred at room temperature under nitrogen. TMSOTF (0.3 mL, 1.7 mmol) was added 
drop-wise and the mixture was allowed to stir for 16 hours. T.l.c. (petrol:ethyl acetate, 2:1) 
indicated formation of a single product (Rf 0.6) and consumption of starting material (Rf 0.3). 
The reaction was neutralized by the drop-wise addition of excess triethylamine (~ 0.6 mL). The 
reaction mixture was filtered on celite®, eluting with ethyl acetate and concentrated in vavuo to 
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afford a yellow clear oil. The residue was purified by flash chromatography (petrol:ethyl acetate, 
10:1) to afford N-octyl-N‟-2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 67 (751 mg, 
77%, α:β, 1:2) as a waxy solid. υmax (thin film) 3259 (w, N-H), 3289 (m, N-H), 1355 (w, S=O), 
1158 (s, S=O) cm
-1
;
 δH (500 MHz, CDCl3) 0.88 (9H, t, J 6.8, CH3), 1.26 (30H, m, CH2), 1.47 - 
1.61 (6H, m, CH2), 2.99 - 3.02 (6H, m, NHCH2 α and NHCH2 β), 3.44 - 3.50 (3H, m, H-5α and 
H-5β), 3.46 -3.60 (3H, H-5‟α, and H-5‟β), 3.94 – 4.05 (3H, m, H-3α and H-3β), 4.01 - 4.02 (3H, 
m, H-2α and H-2β), 4.03-4.05 (1H, m,H-4α), 4.33-4.35 (2H, m, H-4β), 4.46 - 4.58 (18H, m, 
PhCH2), 5.36 - 5.38 (2H, dd, JNH-1 11.0 Hz, J1-2 4.10 Hz,  H-1β), 5.41-5.43 (1H, d, J 10.60 Hz, H-
1α), 5.54-5.60 (3H, m, NH-α, NH-β), 6.98 - 7.53 (45H, m, Ar-Hα and Ar-Hβ); δC (126 MHz, 
CDCl3) 14.1 (CH3), 22.6, 26.7, 28.3, 29.9, 31.7, 43.4 (CH2), 70.0, 70.0 (C-5α, C-5β), 71.7, 71.8 
72.9, 72.3, 73.3, 73.4 (PhCH2), 80.8, 81.1 (C-2α, C-2β), 81.2 (C-3α of C-3β), 82.3 (C-4α), 83.3 
(C-1β), 84.2 (C-3α or C-3β), 88.2 (C-1α),   127.7, 127.7, 127.8, 127.8, 127.9, 127.9, 127.9, 
128.0, 128.2, 128.2, 128.3, 128.4, 128.5, 128.5, 128.6 (Ar-CH), 136.6, 136.7, 136.8, 137.4, 
137,6, 137.8 (Ar-C); m/z (ESI
+
) 633.2975 (M+Na
+
, 7.32%); HRMS (ESI
+
) calculated for 
C34H46N2NaO6S  (M+Na
+
) 633.2975. Found 359.2969. 
 
 
N-decyl-N’-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 68 
2,3,5-Tri-O-benzyl-α,β-D-arabinofuranose 31 (0.5 g, 1.2 mmol), N-(Octyl)-sulfamide 55 (0.3 g, 
1.2 mmol) and crushed, activated 3Å molecular sieves (~ 400 mg) was suspended in dry DCM 
(15 mL) under nitrogen. TMSOTF (220 μL, 1.2 mmol) was added drop-wise at room 
temperature and the mixture was allowed to stir for 16 hours. T.l.c. (petrol:ethyl acetate 5:1) 
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indicated formation of a single product (Rf 0.4) and consumption of starting material (Rf 0.1). 
The reaction was neutralized by the drop-wise addition of excess triethylamine (~ 0.6 mL). The 
reaction mixture was filtered on celite®, eluting with ethyl acetate and concentrated in vavuo to 
afford a yellow clear oil. The residue was purified by flash chromatography (petrol:ethyl acetate, 
10:1) to afford N-decyl-N‟-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl sulfamide 68 (0.6 g, 78%, 
α:β, 1:1.3) as a waxy solid. υmax (thin film); 3288 (w, NH), 1337 (s, S=O), 1155 (w, S=O) cm
-1
;  
δH (500 MHz, methanol-d4) 0.89 (6.9 H, CH3 α and CH3 β ), 1.16 - 1.38 (32.2H, m, CH2), 1.43 - 
1.55 (4.6H, t, J 6.6 Hz, CH2NH), 2.85 - 3.05 (4.6H, m, CH2), 3.48 - 3.65 (4.6H, m, H-5α, H-5β, 
H-5‟α, H-5‟β), 3.86 - 4.29 (5.9H, m, H-2α, H-3α, H-2β, H-3β, H-4β), 4.39 - 4.74 (14.8H, m, 
PhCH2, H-4α), 5.21 (1.3H, d, J1,NH 3.67 Hz, H-1β), 5.30 (1H, d, J1,NH 4.40 Hz, H-1α), 7.09 - 7.44 
(34.5H, m, Ar-H); δC (126 MHz, methanol-d4) 14.5 (CH3), 20.9 (CH2), 23.7 (CH2), 27.9 (CH2), 
30.4 (CH2), 30.4 (CH2), 30.5 (CH2), 30.7 (CH2), 33.1 (CH2), 44.0 (CH2), 44.1 (CH2), 61.5 (CH), 
71.2 (CH), 71.7 (CH), 72.7 (CH), 73.0 (CH), 74.3 (CH), 81.6 (CH), 81.8 (CH), 82.7 (CH), 82.9 
(CH), 83.6 (CH), 85.5 (CH), 88.0 (CH), 89.3 (CH), 89.3 (CH), 128.7, 128.8, 128.8, 128.9, 128.9, 
129.0, 129.1, 129.2, 129.4, 129.5, 138.8, 139.1, 139.2, 139.3, 139.4 (Ar-C); m/z (ESI
+
) 661.3280 
(M+Na
+
, 10%); HRMS (ESI
+
) calculated for C36H50N2NaO6S  (M+Na
+
) 661.3280. Found 
661.3282. 
 
 
N-dodecyl-N’-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 69 
2,3,5-Tri-O-benzyl-α,β-D-arabinofuranose 31 (1.4 g, 3.3 mmol), N-(Dodecyl)-sulfamide 56 (0.88 
g, 3.3 mmol) and crushed, activated 3Å molecular sieves (~ 800 mg) was suspended in dry DCM 
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(25 mL) under nitrogen. TMSOTF (0.6 mL, 3.3 mmol) was added drop-wise at room 
temperature and the mixture was allowed to stir for 16 hours. T.l.c. (petrol:ethyl acetate 3:1) 
indicated formation of a single product (Rf 0.7) and consumption of starting material (Rf 0.2). 
The reaction was neutralized by the drop-wise addition of excess triethylamine (~ 1 mL). The 
reaction mixture was filtered on celite®, eluting with ethyl acetate and concentrated in vavuo to 
afford a yellow clear oil. The residue was purified by flash chromatography (petrol:ethyl acetate 
8:1) to afford N-decyl-N‟-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl sulfamide 69 (1.8 g, 80%, 
α:β, 1:1.3) as a waxy solid. υmax (thin film); 3296 (w, NH), 1341 (s, S=O), 1156 (w, S=O) cm
-1
; 
δH (500 MHz, acetone-d6) 0.88 (6.9H, t, J 7.0 Hz, CH3-α, CH3-β), 1.27-1.51 (41.6H, m, CH2),  
1.53-2.05 (4.6H, m, NHCH2CH2α, NHCH2CH 2β), 2.99-3.07 (4.6H, m, NHCH2α, NHCH2β), 
3.58-3.62 (4.6H, m, CH-5α, CH5β, CH-5‟α, CH-5‟β), 3.98-4.03 (1.0H, m, CH-4α), 4.06-4.18 
(5.6H, m, CH-2α, CH-2β, CH-3α, CH-3β), 4.27-4.31 (1.3H, m, CH-4β), 4.52-4.75 (13.8H, 
PhCH2α, PhCH2β), 5.27 (1.3H, dd, JNH-1 10.1 Hz, J1-2 6.0 Hz, H-1β), 5.33 (1H, dd, JNH-1 10.4 Hz, 
J1-2 3.1 Hz, H-1α), 6.33 (1H, d, 10.5 Hz, NHα), 6.77 (1.3H, d, J 10.1 Hz, NHβ), 7.26-7.40 
(34.5H, Ar-Hα, Ar-Hβ); δC (500 MHz, acetone-d6) 13.7 (CH3), 22.7 (CH2), 26.9 (CH2), 29.4 
(CH2), 29.4 (CH2), 29.4 (CH2), 29.6 (CH2) 29.7 (CH2), 29.7 (CH2), 29.8 (CH2), 32.0 (CH2), 43.2 
(CH2), 43.3 (CH2), 70.5 (CH2),71.0 (CH2), 71.5 (CH2), 71.7 (CH2), 71.9 (CH2), 72.0 (CH2), 73.1 
(CH2), 73.1 (CH2),  80.8 (CH), 81.3 (CH), 81.4 (CH), 82.0 (CH), 82.1 (CH), 83.1 (CH), 83.2 
(CH), 84.7 (CH), 86.9 (CH), 88.5 (CH), 124.4-138.9 (Ar-CH); m/z (ESI
+
) species observed 
(M+Na
+
); (M+Na
+
) peak observed: 689.3573 (32%), peak calculated: 689.3595. 
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N-tetradecyl-N’-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 70 
2,3,5-Tri-O-benzyl arabinofuranose 31 (1.8 g, 4.3 mmol), N-(Tetradecyl)-sulfamide 57 (1.3 g, 
4.3 mmol) and crushed, activated 3Å molecular sieves (~ 800 mg) was suspended in dry DCM 
(50 mL) under nitrogen. TMSOTF (0.8 mL, 4.3 mmol) was added drop-wise at room 
temperature and the mixture was allowed to stir for 16 hours. T.l.c. (petrol:ethyl acetate 5:1) 
indicated formation of a single product (Rf 0.3) and consumption of starting material (Rf 0.1) The 
reaction was neutralized by the drop-wise addition of excess triethylamine (~ 1 mL). The 
reaction mixture was filtered on celite®, eluting with ethyl acetate and concentrated in vavuo to 
afford a yellow clear oil. The residue was purified by flash chromatography (petrol:ethyl acetate 
10:1) to afford N-tetradecyl-N‟-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl sulfamide 70 (1.9 g, 
70%, α:β, 1:1.5) as a waxy solid. υmax (thin film); 3295 (m, NH), 1344 (s, S=O), 1151 (w, S=O) 
cm
-1
;
 δH (500 MHz, chloroform-d) 0.88 (7.5H, m, CH3), 1.25-1.34 (55H, m, CH2), 1.44-1.55 (5H, 
m, NHCH2CH2), 2.95-3.05 (5H, m, NHCH2), 3.47 (1H, dd, J5-5‟ 9.3 Hz, J5-4  7.5 Hz, H-5β), 3.52 
(2.5H, m, H-5α, H-5‟α), 3.55-3.59 (1H, dd, J5‟-5 9.7 Hz, J5‟-4 5.8 Hz, H-5‟β), 3.93-3.96 (2.5H, m, 
H-3α, H-3β), 3.97-3.98 (1.5H, m, H-2β), 3.99-4.01 (1H, m, H-2α), 4.02-4.06 (1H, m, H-4α), 
4.09-4.14 (2.5H, m, NHα, NHβ), 4.20 (1H, t, J 6.2 Hz, NHCH2α), 4.25 (1.5H, t, J 5.3 Hz, 
NHCH2β), 4.32-4.34 ( 1.5H, m, H-4β), 4.41-4.56 (15H, m, PhCH2), 5.36 (1H, dd, J1-2 4.4 Hz, J1-
NH 10.3 Hz, H-1α), 5.41 (1.5H, d, J 10.6 Hz, H-1β), 5.55 (1H, d, J 10.2 Hz, NHα), 5.59 (1.5H, d, 
J 10.8 Hz, NHβ), 7.19-7.40 (37.5H, m, Ar-H); δC (500 MHz, chloroform-d) 14.3 (CH3), 22.8 
(CH2), 26.8 (CH2), 26.9 (CH2), 26.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.6 (CH2), 29.7 (CH2), 29.7 
(CH2), 29.8 (CH2), 29.8 (CH2), 29.8 (CH2), 32.1 (CH2), 43.5 (CH2), 43.6 (CH2), 70.2 (CH2), 71.8 
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(CH2), 71.9 (CH2), 72.1 (CH2), 72.5 (CH2), 73.5 (CH2), 73.6 (CH2), 80.9 (CH), 81.3 (CH), 81.9 
(CH), 82.5 (CH), 83.4 (CH), 84.4 (CH), 84.9 (CH), 88.4 (CH), 127.8-138.0 (Ar-C); m/z (ESI
+
) 
species observed (M+Na
+
); (M+Na
+
) peak observed: 717.3905 (100%), peak calculated: 
717.3908. 
 
 
N-(2-(2-(2-(benzyloxyethoxy)ethoxy)-N’-(2,3,5-tri-O-benzyl-α,β-D-
arabinofuranosyl)sulfamide 71 
N-((2-(2-(2-(benzyloxyethoxy)ethoxy)ethyl)-sulfamide 58 (0.6 g, 1.8 mmol) and crushed, 
activated 3Å molecular sieves (~ 400 mg) was suspended in dry DCM (15 mL) stirred under 
nitrogen. TMSOTF (330 μL, 1.7 mmol) was added drop-wise at room temperature and the 
mixture was allowed to for 16 hours. T.l.c. (petrol:ethyl acetate, 1:1) indicated formation of a 
major product (Rf 0.4) and consumption of starting material (Rf 0.0). The reaction was 
neutralized by the drop-wise addition of excess triethylamine (0.6 mL). The reaction mixture was 
filtered on Celite®, eluting with ethyl acetate and concentrated in vavuo to afford a yellow oil. 
The residue was purified by flash chromatography (petrol:ethyl acetate 2:1) to afford product N-
monobenzyltri(ethylene-N’-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl) sulfamide 71 (0.9 g, 
71%, α:β ~ 1:20); υmax (thin film); 3286 (m, NH), 1341 (s, S=O), 1154 (w, S=O) cm
-1
; δH (500 
MHz, acetone-d6) 3.15-3.28 (5H, m, NHCH2α, NHCH2β), 3.53-3.64 (29H, m, CH2, H-5α, H-5‟α, 
H-5β, H-5‟β), 3.99-4.03 (1H, m, H-4α), 4.07-4.10 (3.5H, m, H-2α, H-3α, H-3β), 4.16-4.18 (1.5H, 
m, H-2β), 4.31-4.34 (1.5H, m, H-4β), 4.47-4.71 (20H, m, PhCH2), 5.30 (1.5H, dd, J1-1‟ 3.3 Hz, J1-
NH 10.0 Hz, H-1β), 5.35 (1H, dd, J1-1‟ 4.4 Hz, J1-NH 10.7 Hz, H-1α), 5.75-5.80 (2.5H, m, NHα, 
Experimental 
58 
 
NHβ), 6.44 (1H, d, J 10.4 Hz, NH-1α), 6.82 (1.5H, d, J 9.9 Hz, NH-1β); δC (500 MHz, acetone-
d6) 43.1 (NHCH2α), 43.1 (NHCH2β), 69.8 (CH2), 70.2 (CH2), 70.4 (CH2), 70.5 (CH2), 70.8 
(CH2), 71.5 (CH2), 71.7 (CH2), 71.9 (CH2), 72.0 (CH2), 72.8 (CH2), 73.1 (CH2), 80.8 (CH), 81.3 
(CH), 81.9 (CH), 82.1 (CH), 83.1 (CH), 84.8 (CH), 86.9 (CH), 88.6 (CH), 88.6 (CH),127.5-
128.6 (Ar-CH), 138.2-139.2 (Ar-C); m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak 
observed: 743.2983 (100%), peak calculated: 743.2973. 
 
 
N-hexyl-N’-(β-D-arabinofuranosyl)sulfamide 72 
Activated Pd-black (60 mg, 5% weight of 66) was added slowly to a solution of N-Hexyl-N’-
(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 66  (600 mg, 1.0 mmol) in methanol:acetic 
acid (10 mL of a 9:1 v/v mixture). The flask was evacuated and purged with nitrogen three times, 
before being placed under an atmosphere of hydrogen. The solution was allowed to stir for 2 
days at room temperature. T.l.c. (ethyl acetate:acetone, 3:2) indicated formation of two products 
(Rf 0.4 and 0.3), corresponding to the α- and β-anomers and consumption of starting material (Rf 
0.8). The flask was evacuated and placed under nitrogen. The mixture was filtered on Celite® 
(eluting with methanol ~30 mL) and concentrat in vacuo to afford a yellow oil. The residue was 
purified by flash column (ethyl acetate:acetone, 3:1) to afford and  N-hexyl-N’-(β-D-
arabinofuranosyl) sulfamide 72 (135 mg, 65%, from β anomer) as a white solid, m.p. 125-128˚C 
(ethyl acetate/petrol). [α]D
20
 -25.2 (c 1.0 in MeOH); υmax (diffraction) 3330 (br, OH), 3315 (N-H), 
1328 (S=O), 1142 (S=O) cm
-1; δH (500 MHz, acetone-d6) 0.85 (3H, t, J 7.0 Hz, CH3), 1.23-1.35 
(6H, m, CH2), 1.51 (2H, m, NHCH2CH2), 2.97-3.04 (2H, m, NHCH2), 3.56 (1H, d, J 12 Hz, H-
Experimental 
59 
 
5‟), 3.64-3.63 (2H, m, H-2, H-3), 3.83-3.88 (2H, m, H-4, H-5), 3.89 (1H, s, OH-5), 4.33 (1.5H, 
br. s, OH-2, OH-3), 4.41 (1H, d, J 7.4 Hz, H-1), 5.68 (1H, t, J 6.0 Hz, NHCH2), 6.73 (0.5H, s, 
NH-1); δC (126 MHz, acetone-d6) 14.2 (CH3), 23.1 (CH2), 27.0 (CH2), 29.9 (CH2), 32.1 (CH2), 
43.6 (CH2NH), 66.9 (CH-5), 66.9 (CH-5‟), 68.5 (CH-4), 70.8 (CH-2 or CH-3), 74.0 (CH-2 of 
CH-3), 85.6 (CH-1); m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak observed: 335.1262 
(100%), peak calculated: 335.1247. 
 
 
N-octyl-N’-(β-D-arabinofuranosyl)sulfamide 73 
Activated Pd-black (45 mg, 5% weight of 67) was added slowly to a solution of N-Octyl-N‟-
(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 67 (640 mg, 1.1 mmol) in methanol:acetic 
acid (10 mL of a 9:1 v/v mixture). The flask was evacuated and purged with nitrogen three times, 
before being placed under an atmosphere of hydrogen. The solution was allowed to stir for 2 
days at room temperature. T.l.c. (petrol: ethyl acetate, 1:5) indicated formation of two products 
(Rf 0.21 and 0.23), corresponding to the α- and β-anomers and consumption of starting material 
(Rf 0.80). The flask was evacuated and placed under nitrogen. The mixture was filtered on 
Celite® (eluting with methanol ~ 30 mL) and concentrat in vacuo to afford a yellow oil. The 
residue was purified by flash column (petrol:ethyl acetate, 1:5) to afford and N-octyl-N’-(β-D-
arabinofuranosyl)sulfamide 73 (150 mg, 60%, from β anomer) as a white solid, m.p. 125-128˚C 
(ethyl acetate/petrol). [α]D
20
 -14.0 (c, 1.0 in MeOH); υmax (diffration); 3330 (br, OH), 3310 (N-
H), 1323 (S=O), 1142 (S=O); δH (500 MHz, acetone-d6) 0.88 (3 H, t, J 6.60 Hz, CH3), 1.17 - 
1.44 (10H, m, CH2), 1.49 - 1.63 (2H, m, CH2CH2NH), 2.82 (1H, OH-2 or OH-5), 2.85 - 3.06 
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(2H, m, NCH2), 3.55 (2H, d, J 11.00 Hz, H-5), 3.63 - 3.65 (2H, m, H-2 and OH-3), 3.71 - 3.80 
(1H, m, H-3), 3.80 - 3.84 (1H, m, H-5‟), 3.84-3.89 (1H, m, H-4), 4.21 (1H, s, OH-2 or OH-5), 
4.39-4.43 (1H, dd, J1-NH 9.8 Hz, J1-2 6.9 Hz, H-1β), 5.65 (1H, t, J=5.69 Hz, NH),  6.67 (1H, d, 
J=8.80 Hz, NH). δC (126MHz ,acetone-d6) 14.3 (CH3), 23.2 (CH2), 27.2 (CH2), 29.8 (CH2), 29.8 
(CH2), 30.0 (CH2), 30.2 (CH2), 43.6 (NCH2), 67.1 (C-5), 68.6 (C-4), 70.8 (C-2), 74.1 (C-3), 85.7 
(C-1); m/z (ES
+
) 363.1552 (M+Na
+
, 70%); HRMS (ES
+
) calculated for C13H28N2NaO6S 
(M+Na
+
) 363.1552. Found 353.1560. 
 
 
N-decyl-N’-(β-D-arabinofuranosyl)sulfamide 74 
Activated Pd-black (40 mg, 5% weight of 68) was added slowly to a solution of N-decyl-N’-
(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl) sulfamide 68 (0.6 g, 0.9 mmol) in methanol:acetic 
acid (10 mL of a 9:1 v/v mixture). The flask was evacuated and perged with nitrogen three times, 
before being placed under an atmosphere of hydrogen. The solution was allowed to stir over 
night at room temperature under hydrogen. T.l.c. (petrol: ethyl acetate 1:5) indicated formation 
of two products (Rf 0.1 and 0.2), corresponding to the α- and β-anomers and consumption of 
starting material (Rf 0.8). The flask was evacuated and placed under nitrogen before filtration on 
celite® (eluting with methanol ~ 30 mL) and concentrated in vacuo to afford a yellow oil. The 
residue was purified with flash column (petrol:ethyl acetate 1:5) to afford N-decyl-N’-(β-D-
arabinofuranosyl)sulfamide 74 (116 mg, 62%, from β anomer) as a white solid, m.p. 125-128˚C 
(ethyl acetate/petrol). [α]D
20
 -32.4 (c, 1.0 in MeOH); υmax (diffration); 3310 (br, OH), 1323 (s, 
S=O), 1142 (s, S=O); δH (500 MHz, acetone-d6) 0.87 (3 H, t, J 6.60 Hz, CH3), 1.17 - 1.43 (14H, 
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m), 1.54 (2 H, q, J 6.97 Hz, CH2),  2.82 (1 H, s, OH-2 or OH-5) 2.94 - 3.15 (2 H, m, CH2), 3.55 
(1 H, d, J 11.37 Hz, H-5), 3.61 - 3.70 (2 H, m, H-2, OH-3), 3.77 (1 H, d, J 3.30 Hz, H-3), 3.80 - 
3.94 (2 H, m, H-4, H-5‟), 4.23 (1 H, br. s, OH-2 or OH-5), 4.41 (1 H, t, J 7.52 Hz, H-1β), 5.64 (1 
H, t, J 5.69 Hz, NH-β), 6.68 (1 H, d, J 9.17 Hz, NH-α); 13C NMR (126 MHz, acetone) δH ppm 
13.7 (CH3), 22.7 (CH2), 26.9 (CH), 29.4 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 
31.9 (CH2), 43.2 (CH), 67.83 (CH), 70.65 (CH), 73.72 (CH), 85.09 (CH); m/z (ESI
+
) 391.1872 
(M+Na
+
, 100%); HRMS (ESI
+
) calculated for C15H32N2NaO6S  (M+Na
+
) 391.1872. Found 
391.1873. 
 
 
N-dodecyl-N’-(β-D-arabinofuranosyl) sulfamide 75 
Activated Pd/C (0.6 g, 40% weight of 69) was added slowly to a solution of N-Dodecyl-N’-
(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 69 (1.2 g, 1.8 mmol) in methanol:acetic 
acid (20 mL of a 9:1 v/v mixture). The flask was evacuated and perged with nitrogen three times, 
before being placed under an atmosphere of hydrogen. The solution was allowed to stir for two 
days at room temperature under hydrogen. T.l.c. (ethyl acetate:acetone, 3:2) indicated formation 
of two products (Rf 0.4 and 0.3), corresponding to the α- and β-anomers and consumption of 
starting material (Rf 0.8). The flask was evacuated and placed under nitrogen before filtration on 
celite® (eluting with methanol ~50 mL) and concentrated in vacuo to afford a yellow oil. The 
residue was purified with flash column (ethyl acetate:acetone, 3:1) to afford N-Dodecyl-N’-(α-D-
arabinofuranosyl) sulfamide (40 mg) and N-dodecyl-N’-(β-D-arabinofuranosyl) sulfamide 75 
(280 mg, 60%) as a white solid, m.p. 120-122˚C (petrol/ethyl acetate); [α]D
20
 -22.2 (c, 1.0 in 
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MeOH); υmax (diffration); 3331 (br, OH), 3310 (N-H), 1321 (S=O), 1142 (S=O); δH (500 MHz, 
methanol-d4) 0.90 (3H, t, J 7.0 Hz, CH3), 1.29 (18H, m, CH2), 1.51-1.54 (2H, m, NHCH2CH2), 
2.97-3.02 (2H, m, NHCH2), 3.52-3.58 (3H, m, H-2, H-3, H-5‟), 3.82-3.85 (2H, m, H-4, H-5), 
4.30 (1H, d, J 7.4, H-1); δC (126 MHz, methanol-d4) 13.3 (CH3), 22.6 (CH2), 26.8 (CH2), 29.2 
(CH2), 29.3 (CH2), 29.3 (CH2), 29.5 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2),  31.9 
(NHCH2CH2), 42.8 (NHCH2), 67.0 (CH2-5), 68.5 (CH2-4), 70.2 (CH2-2), 73.7 (CH2-3), 85.4 
(CH2-1); m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak observed: 419.2186 (100%), 
peak calculated: 419.2186. 
 
 
N-tetradecyl-N’-(β-D-arabinofuranosyl) sulfamide 76 
Activated Pd/C (0.6 g 40% weight of 70) was added slowly to a solution of N-Tetradecyl-N’-
(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl) sulfamide 70 (1.1 g, 1.6 mmol) in methanol:acetic 
acid (20 mL of a 9:1 v/v mixture). The flask was evacuated and perged with nitrogen three times, 
before being placed under an atmosphere of hydrogen. The solution was allowed to stir for two 
days at room temperature under hydrogen. T.l.c. (ethyl acetate:acetone, 3:2) indicated formation 
of two products (Rf 0.4 and 0.3), corresponding to the α- and β-anomers and consumption of 
starting material (Rf 0.8). The flask was evacuated and placed under nitrogen before filtration on 
celite® (eluting with methanol ~ 50 mL) and concentrated in vacuo to afford a yellow oil. The 
residue was purified with flash column (ethyl acetate:acetone, 3:1) to afford N-tetradecyl-N’-(β-
D-arabinofuranosyl)sulfamide 76 (244 mg, 60%, from β anomer) as a white solid, m.p. 119-
120˚C (petrol/ethyl acetate); [α]D
20
 -22.2 (c, 1.0 in MeOH); υmax (diffration); 3335 (br, OH), 3310 
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(N-H), 1142 (S=O); δH (500 MHz, methanol-d4) 0.90 (3H, t, J 7.0 Hz, CH3), 1.22-1.32 (22H, m, 
CH2), 1.50-1.54 (2H, m, NHCH2CH2), 2.96-3.02 (2H, m, NHCH2), 3.52-3.57 (3H, m, H-2, H-3, 
H-5‟), 3.58-3.84 (2H, m, H-4, H-5), 4.09 (0.5H, aq, J 7.0 Hz, NH), 4.30 (1H, d, J1,2 7.5 Hz, H-1); 
δC (126 MHz, methanol-d4) 13.3 (CH3), 22.6 (CH2), 26.8 (CH2), 29.2 (CH2), 29.3 (CH2), 29.3 
(CH2), 29.5 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2),  31.9 (NHCH2CH2), 42.8 (NHCH2), 67.0 
(CH2-5), 68.5 (CH2-4), 70.2 (CH2-2), 73.7 (CH2-3), 85.4 (CH2-1); m/z (ESI
+
) species observed 
(M+Na
+
); (M+Na
+
) peak observed: 447.2499 (91%), peak calculated: 447.2505. 
 
 
N-(2-(2-(ethoxy)ethoxy)ethanol -N’-(β-D-arabinofuranosyl)sulfamide 77 
Activated Pd/C (400 mg 40% weight of 71) was added slowly to a solution of N-octyl-N‟-(2,3,5-
tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 71 (760 mg, 1.1 mmol) in methanol:acetic acid 
(10 mL of a 9:1 v/v mixture). The flask was evacuated and purged with nitrogen three times, 
before being placed under an atmosphere of hydrogen. The solution was allowed to stir for 2 
days at room temperature. T.l.c. (ethyl acetate: acetone, 3:2) indicated formation of one product 
(Rf 0.2), corresponding to the mixture of α- and β-anomers and consumption of starting material 
(Rf 0.70). The flask was evacuated and placed under nitrogen. The mixture was filtered on 
Celite® (eluting with methanol ~ 30 mL) and concentrat in vacuo to afford a yellow oil. The 
residue was purified by flash column (DCM:methanol, 6:1) to afford N-(2-(2-
(ethoxy)ethoxy)ethanol-N’-(α,β-D-arabinofuranosyl)sulfamide 77 (198 mg, 50%, β is the major 
anomer, α:β, ~ 1:20) as a clear oil. υmax (thin film); 3334 (br, OH), 3314 (N-H), 1328 (S=O); δH 
(500 MHz, methanol-d4) 3.15-3.30 (2H, m, NHCH2), 3.55-3.72 (4H, m, CH2, H-2, H-3, H-5), 
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3.84-3.87 (2H, m, H4, H-5), 4.33 (1H, d, J1,2 7.5 Hz, H-1); δC (500 MHz, methanol-d4) 42.7 
(CH2), 61.0 (CH2), 67.2 (CH2),  68.6 (CH), 69.8 (CH2), 69.9 (CH2),70.2 (CH), 70.6 (CH), 72.5 
(CH2), 73.8 (CH), 85.5 (CH);  m/z (ESI
+
) species observed (M+Na
+
); (M+Na
+
) peak observed: 
383.1094 (100%), peak calculated: 383.1095. 
 
 
N-decyl-N’-(2,3,5-tri-O-benzyl-α,β-D-arabinofuranosyl)sulfamide 78 
N-decyl sulfamide 55 (438.7 mg, 1.85 mmol) was added to a solution of cude 2,3,5-Tri-O-
benzyl-α,β-D-arabinofuranosyl bromide 33 (0.92 mmol) and TTBP (576.3 mg, 2.3 mmol) in dry 
DCM (15 mL) under nitrogen. After 16 hr, t.l.c. (petrol:ethyl acetate, 5:1) indicated formation of 
a major product (Rf 0.3) and  unreacted starting marterial 33 (0.1) and 33 (0.0). The reaction 
mixture was diluted in DCM (50 mL), washed with sodium bicarbonate (3 x 50 mL of a 
saturated solution) and brine (1 x 50 mL of a saturated solution). The organic phase was dried 
(MgSO4), filtered and concentrated in vacuo to afford a yellow oil. The residue was purified by 
flash chromatography (petrol,ethyl acetate, 5:1) to afford a mixture of  N-decyl-N’-(2,3,5-tri-O-
benzyl-α,β-D-arabinofuranosyl)sulfamide 78 (10%, α:β, 2:1) as a waxy solid. δH (500 MHz, 
CHCl3-d) 0.88 (9 H, CH3 α and CH3 β ), 1.24 - 1.30 (56H, m, CH2), 1.42 - 1.58 (6H, m, CH2), 
2.94 - 3.01 (6H, m, CH2), 3.40 - 3.60 6H, m, H-5α, H-5β, H-5‟α, H-5‟β), 3.86 - 4.38 (8H, m, H-
2α, H-3α, H-2β, H-3β, H-4β), 4.40 - 4.74 (20H, m, PhCH2, H-4α), 5.21 (1H, dd, J1,NH  10.5 Hz, 
J1,2 4.5 Hz, H-1β), 5.30 (1H, d, J1,NH 11.0 Hz, H-1α), 7.09 - 7.44 (45H, m, Ar-H); m/z (ESI
+
) 
species observed (M+Na
+
); (M+Na
+
) peak observed: 661.3289 (100%), peak calculated: 
661.3282.
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